



Review

Dynamic behaviors of α -synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration

Fred Yeboah^{a,1}, Tae-Eun Kim^{b,1}, Anke Bill^{a,*}, Ulf Dettmer^{b,*}

^a Novartis Institute for Biomedical Research, Chemical Biology and Therapeutics, Cambridge, MA 02139, USA

^b Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA

ABSTRACT

α -Synuclein (α S) and tau have a lot in common. Dyshomeostasis and aggregation of both proteins are central in the pathogenesis of neurodegenerative diseases: Parkinson's disease, dementia with Lewy bodies, multi-system atrophy and other 'synucleinopathies' in the case of α S; Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy and other 'tauopathies' in the case of tau. The aggregated states of α S and tau are found to be (hyper)phosphorylated, but the relevance of the phosphorylation in health or disease is not well understood. Both tau and α S are typically characterized as 'intrinsically disordered' proteins, while both engage in transient interactions with cellular components, thereby undergoing structural changes and context-specific folding. α S transiently binds to (synaptic) vesicles forming a membrane-induced amphipathic helix; tau transiently interacts with microtubules forming an 'extended structure'. The regulation and exact nature of the interactions are not fully understood. Here we review recent and previous insights into the dynamic, transient nature of α S and tau with regard to the mode of interaction with their targets, the dwell-time while bound, and the cis and trans factors underlying the frequent switching between bound and unbound states. These aspects are intimately linked to hypotheses on how subtle changes in the transient behaviors may trigger the earliest steps in the pathogenesis of the respective brain diseases. Based on a deeper understanding of transient α S and tau conformations in the cellular context, new therapeutic strategies may emerge, and it may become clearer why existing approaches have failed or how they could be optimized.

1. Introduction

In a sense, the study of protein folding is a quandary: conventional NMR, cryo-EM, or X-ray crystallography can solve the structure of a purified protein but does so by taking the protein out of its biological context. On the other hand, various cell biological and biochemical techniques can provide insight into a protein's behavior within a cellular context, but the information on its structure at atomic-level resolution is limited. That does not seem to be a problem for many proteins because their *in vitro* structures are a good approximation of those in the cell. However, it becomes a greater challenge when studying 'intrinsically disordered' proteins. Such proteins (or at least significant portions of them) adopt a more-or-less random-coil ('unfolded') structure in solution *in vitro*, but this does not rule out that context-specific folding/assembly states can arise inside cells. On the contrary, for many 'intrinsically disordered' proteins, transient folding has been proposed, but the dynamic nature of such states can render the proteins elusive to precise characterization. The stakes arguably become higher when the proteins under investigation are implicated in disease. Indeed, two key proteins in neurodegenerative diseases, α -synuclein (α S) in Parkinson's disease (PD), Dementia with Lewy bodies (DLB), and other 'synucleinopathies' and tau in Alzheimer's disease (AD), frontotemporal

dementia (FTD), and other 'tauopathies' are still not yet well understood regarding their dynamic conformational behavior in cells. α S and tau, which both form insoluble aggregates in the brain under disease conditions, have been described to be largely soluble in their native states while transiently interacting with cellular targets: α S with (synaptic) vesicles, tau with microtubules (MTs). This indicates that a contextual understanding of the transient and dynamic behavior of both proteins at the chemical, molecular, and cellular level may be required to understand synucleinopathies and tauopathies and develop therapeutic strategies through new perspectives. Here, we discuss recent advances in understanding cellular α S and tau dynamics in the context of the previous literature. Our special focus will be molecular 'cis' and 'trans' determinants undergirding α S and tau transient behavior. We conclude with some remarks on possible therapeutic strategies in light of our analysis.

2. α S

2.1. α S in health and disease

Since the first discoveries of α S aggregation in Lewy bodies (Spillantini et al., 1997) (see below), hundreds of studies have probed

* Corresponding authors.

E-mail addresses: anke.bill@novartis.com (A. Bill), udetmer@bwh.harvard.edu (U. Dettmer).

¹ These authors contributed equally.

the precise structure and characteristics of physiological α S. There are many fine reviews on structure/function (Bendor et al., 2013; Mor et al., 2016; Villar-Piqué et al., 2016; Wang et al., 2016; Cremades et al., 2017), genetic interactions (Schneider and Alcalay, 2017; Nussbaum, 2018), and neurotoxicity (Lashuel et al., 2013; Villar-Piqué et al., 2016; Berrocal et al., 2015; Ghosh et al., 2015; Wong and Krainc, 2017; Roberts and Brown, 2015) of α S, but what is significant to highlight here is that despite years of research, the precise function, subcellular distribution, and context-specific behavior of α S are still under investigation. It is likely that these properties are all intimately linked.

In mature neurons, including dopaminergic neurons (George et al., 1995; Iwai et al., 1995), α S predominantly resides in presynaptic nerve terminals, which has prompted the hypothesis that α S may be involved in regulating dopamine release (Murphy et al., 2000; Gedalya et al., 2009; Nemani et al., 2010). Considerable evidence suggests that α S helps regulate (synaptic) vesicle trafficking (Abeliovich et al., 2000; Chandra et al., 2004; Nemani et al., 2010; Scott and Roy, 2012; Wang et al., 2014; Vargas et al., 2014; Logan et al., 2017). This role of α S is consistent with its well-documented propensity to bind to small vesicles *in vitro*, which is mediated by its formation of transient amphipathic helices at highly curved membranes (see 2.2) (Davidson et al., 1998; Chandra et al., 2003; Jao et al., 2004, 2008). PD and DLB cytopathology and neurodegeneration are characterized by α S accumulation into Lewy bodies, large intracellular aggregates whose major component is α S. However, the exact relationship between these lesions and dopaminergic neuronal death in the substantia nigra pars compacta and eventual PD symptoms, such as bradykinesia and muscular tremors (Kalia and Lang, 2015), is not fully understood. Similarly, we lack understanding of the exact pathogenic significance of cortical Lewy bodies in DLB. How and under what conditions α S aggregates have been areas of much inquiry and debate.

2.2. α S transiently binds to synaptic vesicles

Early biochemical characterizations of purified bacterially-expressed α S identified the protein to be soluble (George et al., 1995; Irizarry et al., 1996), which confirmed previous immunogold-EM data that detected α S throughout the cytoplasmic matrices in axon terminals (Nakajo et al., 1994). Subsequent biophysical and biochemical studies, however, reported that α S can bind to small unilamellar and multilamellar vesicles (Davidson et al., 1998; Jo et al., 2000) and detergent micelles (Eliezer et al., 2001). Chemically crosslinked α S in SH-SY5Y cell homogenates was also identified in vesicle fractions by flotation centrifugation (Kim et al., 2006), but this observation did not seem to directly contradict the generally soluble nature of α S, because fractionated brain extracts revealed only a weak association of α S with synaptic vesicles (Kahle et al., 2001; Fortin et al., 2004). Similarly, photobleaching microscopy indicated that α S interacts only weakly with membranous elements of the nerve terminal, and each molecule appears to switch rapidly between the aqueous cytosol and the membrane (Fortin et al., 2004, 2005). While methods to interrogate the function of α S vis-à-vis synaptic vesicles (Bendor et al., 2013; Burré, 2015; Lou et al., 2017; Logan et al., 2017; Almandoz-Gil et al., 2018; Liang and Tamm, 2018; Zhang et al., 2018) became a natural implication of such studies, this function is still not well understood (for other proposed functions, see review by Bendor et al., 2013). Nevertheless, what has emerged is a nuanced picture of α S – an aqueously soluble protein that can transiently interact with vesicular membranes.

Recent studies have supplemented established biophysical and microscopy techniques by using new technologies to quantify the transient nature of α S. Single-molecule microscopy combined with photobleaching identified an average of seventy α S molecules bound to each vesicle, with the α S molecules situated 10 nm apart from each other (Fakhree et al., 2016). Moreover, the use of phospholipid bilayer nanodiscs, which had been previously used to study α S-Ca²⁺ interactions

(Zhang et al., 2014), and bacterially purified α S allowed for α S-membrane association and dissociation kinetics to be calculated *in vitro* (e.g., an off-rate of $0.015 \pm 0.006 \text{ s}^{-1}$) (Viennet et al., 2018). However, data generated by *in vivo* multiphoton fluorescence recovery after bleaching (FRAP) coupled with murine cranial window surgery were consistent with the existence of at least two pools of α S in terminals with lower levels of mobility than measured previously. The observed $t_{1/2}$ for axonal terminal photobleaching recovery (~ 2 min) in the mice was much slower than that measured in a photobleaching study of GFP-tagged α S at presynaptic terminals in an acute dissociated hippocampal cell culture system (< 10 s) (Fortin et al., 2005), or YFP-tagged α S in *C. elegans* body wall muscle (< 10 s) (van Ham et al., 2008). In addition to the presynaptic terminal, the turnover and mobility of α S in the somatic compartment of cortical neurons was measured by Unni et al., 2010. In contrast to the discrepancy between their presynaptic terminal results and those reported in the literature, the rapid mobility of α S-GFP measured within the soma (< 5 s) was in good agreement with these previous studies of α S mobility. This suggested that the cellular context of α S may influence transient binding affinity and kinetics (Unni et al., 2010; Spinelli et al., 2014).

This state of equilibrium between soluble and membrane-associated forms of α S is expected to be finely balanced and tightly regulated. Familial PD mutations as well as engineered variants have been observed to shift the balance towards misfolding, insolubility, inclusion formation, and cell toxicity (Brucale et al., 2009; Lázaro et al., 2014; Dettmer et al., 2017; Íñigo-Marco et al., 2017) (discussed in further detail below). Consequently, such adverse changes in neuronal cells pose functional problems in vesicle trafficking, recycling, and neurotransmitter release (Xu et al., 2002, 2016; Lotharius et al., 2002; Busch et al., 2014). Even overexpressed wildtype α S has been shown to undergo accelerated aggregation (Lee et al., 2002; Raiss et al., 2016) and display many of the aforementioned phenotypes (Larsen et al., 2006; Nemani et al., 2010; Soper et al., 2008; Lundblad et al., 2012; Lautenschläger et al., 2018). In short, these observations highlight the transient nature of wildtype α S and the importance for the molecule to remain dynamic to keep cell toxicity at bay.

2.3. α S transiently exists in a variety of monomeric and multimeric forms

Soluble α S had long been believed to exist solely as an unfolded monomer, both *in vitro* and *in vivo*. Less than a decade ago, emerging studies on the conformation of α S began to posit that the protein can exist in part physiologically as a soluble, higher-ordered multimer, principally a tetramer (Wang et al., 2011; Bartels et al., 2011; Dettmer et al., 2013; Gurry et al., 2013; Killinger and Mszczynska, 2016; Luth et al., 2015). Several biochemical as well as *in-cell* NMR studies responded by defending the classical view of α S as a natively unfolded monomer in cells (Binolfi et al., 2012; Fauvet et al., 2012; Burré et al., 2013; Theillet et al., 2016). A review on α S homeostasis (Dettmer et al., 2016) highlighted the debate and suggested specific reasons for why certain studies reported the successful purification of tetrameric/multimeric α S whereas others did not: 1) multimer stability might be tissue-specific (Bartels et al., 2011; Burré et al., 2013; Westphal and Chandra, 2013; Luth et al., 2015); 2) α S purification *in vitro* under non-denaturing conditions could stabilize multimers, but the exact parameters for successful multimer purification are not fully understood (Bartels et al., 2011; Gould et al., 2014; Mor et al., 2016); and 3) under certain conditions, an undiscovered multimer-stabilizing molecule (perhaps one or more lipid molecules) may be lost during purification (Luth et al., 2015). Because of the difficulty of α S multimer purification and stabilization, intact-cell methods such as the application of cell-penetrant cross-linkers to cells and brain tissue (Dettmer et al., 2013, 2015a,b; Dettmer et al., 2017; Kim et al., 2016; Nuber et al., 2018) as well as fluorescent-protein complementation (Dettmer et al., 2015a; Kothawala et al., 2012; Dimant et al., 2013; Moussaud et al., 2015; Cai et al., 2018) became increasingly important for documenting

multimeric α S arrangements. Intact-cell NMR, an elegant method that was used to demonstrate the *in vivo* relevance of unfolded soluble α S (Theillet et al., 2016), is 'blind' to multimeric or membrane-associated α S molecules (Alderson and Bax, 2016). A crosslinking study that compared the outcome of crosslinking intact cells vs. lysates demonstrated that α S and β S putative tetramers (60 kDa) were prominent in intact cells but largely disassembled in crude cell lysates; only in highly concentrated ('crowded') cell lysates could some multimeric α S be trapped by crosslinking (Dettmer et al., 2013). These findings were consistent with a model in which α S multimerization is highly dependent on the intact cellular environment. Relevant factors that promote α S multimerization inside cells could be general 'molecular crowding' or the transient but frequent interaction with specific cellular factors such as membrane lipids, organelles or other biomolecules. Obviously, dilution by cell lysis reduces crowding and disrupts any weak transient interactions that may exist. Recently, an elegant *in vitro* study demonstrated that transient α S-membrane interactions may indeed be the first

'intrinsically disordered proteins' upon binding to ligands is well established, no previous report had described folding assisted by intermittent contact with a cofactor (in this case: membrane lipids). This remarkable study is in agreement with several reports on soluble α S multimers (Bartels et al., 2011; Dettmer et al., 2013, 2015a,b; Dettmer et al., 2017; Gould et al., 2014; Gurry et al., 2013; Iljina et al., 2016; Killinger and Moszczynska, 2016; Kim et al., 2018; Luth et al., 2015; Nüber et al., 2018; Trexler and Rhoades, 2012; Wang et al., 2011; Westphal and Chandra, 2013). The relevance of multimeric α S at membranes has also been highlighted in other studies, e.g., in the context of mediating SNARE complex assembly (Burré et al., 2014; Burré et al., 2015) and vesicle clustering (Wang et al., 2014). Fig. 1A illustrates a model of dynamic cellular α S behavior in health, centered around the idea of (vesicle) membrane-assisted, transient α S folding and assembly (Rovere et al., 2018). In this model, α S monomer and multimer levels are highly transient, dynamic, and sensitive to environmental factors. Fig. 1B highlights potential mechanisms of synu-




Fig. 1. Transient cellular behavior of α S. A, Physiological situation: Coming off the ribosome, α S is soluble, unfolded, and monomeric. Upon binding to vesicular membranes, it adopts helical fold. Folded monomers transiently assemble to form metastable multimers/tetramers on membranes. Multimers/tetramers are only weakly membrane-associated and likely in an equilibrium with cytosolic multimers/tetramers. Cytosolic tetramers/multimers may have an intrinsic propensity to disassemble and eventually unfold, initiating a new cycle. B, Pathological situation (pathological states are in red): perturbed cellular α S homeostasis increases i) the levels of aggregation-prone unfolded monomers in the cytosol, or ii) the level of membrane-associated monomeric α S. Excess soluble α S monomers may be the starting point of cytosolic fibrillar α S aggregation (top left), while excess membrane association may either cause fibrillar α S aggregation via 'nucleation' (bottom right) or membranous non-fibrillar α S aggregation (bottom left). The role of phosphorylation at Ser129 is unclear. While primarily considered a pathological event before or in response to fibrillar aggregation (red), there may also be physiological aspects of this post-translational modification (blue). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

step towards native α S- α S assembly (Rovere et al., 2018). The authors investigated the interplay of α S with 13:0 phosphatidyl-choline small unilamellar vesicles. By modulating α S binding through phase transitions of the vesicle lipids, soluble helical α S species could be reconstituted that behaved as multimers. While folding of certain

cleinopathy initiation based on this model; the illustration takes into account reports on excess soluble α S monomers as the starting point of cytosolic fibrillar α S aggregation (Burré et al., 2015) (top left), fibrillar α S aggregation that is mediated by excess membrane binding via 'nucleation' (Galvagnion et al., 2015) (bottom right), as well as

membranous non-fibrillar α S aggregation as an emerging concept (Nuber et al., 2018; Dettmer et al., 2017; Shahmoradian et al., 2019) (bottom left).

2.4. Molecular determinants of the transient nature of α S

Across the 140 amino acids that span α S, the protein is often sub-




Fig. 2. Molecular determinants of the transient nature of α S. Top left: the 140-aa sequence of human wildtype α S contains 9 semi-conserved 11-aa repeats with the core consensus motif ‘KTKEGV’. Highly conserved repeats are indicated in dark grey, poorly conserved repeats in light grey. Bottom left: color-coded schematic of repeats 1–7 of human α S by aligning the aa sequence via the KTKEGV motifs. Blue indicates basic (light blue: histidine), red: acidic, purple: polar uncharged, and black: non-polar residues. In addition to KTKEGV, the polar character of positions 1 and 9 as well as the non-polar, hydrophobic character of positions 8, 10, and 11 are relatively well conserved. Repeats 1–9 are interrupted only once: by ‘ATVA’ between repeat 4 and 5. Right: Color-coded schematic of α S repeats 1–7 (omitting ‘ATVA’ between repeats 4 and 5) in an 11/3 helical wheel, embedded in the outer leaflet of a curved vesicle membrane (negatively charged lipid head-groups in red, fatty acid ‘tails’ in black). The helix is stabilized by hydrophobic interactions (grey area) and electrostatic interactions (blue area). Certain structural aspects such as the presence of polar threonines as well as the small and ‘helix-breaking’ glycine prevent the formation of a highly stable helix. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

divided into three regions: the N-terminal region (amino acids 1–60), the ‘NAC’ (non-amyloid component) domain (amino acids 61–95), and the C-terminal region (amino acids 96–140) (Mor et al., 2016). The N-terminal region has been of immense interest to better understand the molecular determinants for α S transient membrane-binding behavior, because early studies identified this region to contain amino acid repeat motifs that resemble lipid-binding domains often observed in apolipoproteins (George et al., 1995). Biochemical, cell biological and biophysical studies have shed much light on how α S ‘cis’ determinants (Fusco et al., 2014; Lokappa et al., 2014; Lee et al., 2016; Dettmer et al., 2017) and ‘trans’ factors such as vesicle membrane composition (Pfefferkorn et al., 2012; Zhang et al., 2014; Galvagnion, 2017; Rovere et al., 2018; Fecchio et al., 2018) may govern α S transient binding to artificial and biological membranes.

Different regions of the protein have been shown to have different binding affinities for charged lipid membranes. The first 25 residues in the N-terminus have been suggested to ‘anchor’ into the bilayer (Fusco et al., 2018), with certain key residues (M1, V3, F4, and L8) stabilizing α S at membranes via Van der Waals interactions, while other residues (K6, K10, and K12) interact electrostatically with negatively-charged lipid head groups (Pirc and Ulrih, 2015; Fusco et al., 2016). Due to the repeated structure of α S (6–7 imperfect repeats of 11 aa with the consensus sequence of the repeat motifs being KTKEGV), this mechanism can be extended to the first ~95 aa of the protein. The positively-charged Lys residues have been suggested to interact with negatively-charged lipid head groups when the N-terminus of α S forms a membrane-induced, amphipathic 11/3 helix (3.67 amino acids per turn) (Alderson and Markley, 2013), which allows the Lys residues to lie perpendicular to the helical axis on a membrane (Jao et al., 2008). In contrast, nonpolar amino acid residues can partially dip into the membrane bilayer (~1–5 Å below lipid head groups) (Wietek et al.,

2013; Tsigelny et al., 2012; West et al., 2016; Cheng et al., 2013), especially where lipid packing defects exist, and interact with the lipid carbon chains (Nuscher et al., 2004; Ouberaï et al., 2013). However, in the α S membrane-induced, amphipathic 11/3 helix, some non-polar residues are exposed to the aqueous phase, and some polar residues are embedded into the nonpolar lipid bilayer, most prominently threonine residues (see Fig. 2), leading to imperfect amphipathic helix formation.

Consequently, the specific arrangement of charged residues, polar lipid head groups, and nonpolar carbon chains seems to manifest the transient nature of α S-membrane binding (Wang et al., 2016; Dettmer et al., 2017).

This principle can be confirmed by observing how rationally engineered mutants within the canonical repeat motif, KTKEGV, that ‘correct’ the imperfect hydrophobicity within the hydrophobic half of the α S membrane-induced amphipathic helix can thereby abolish the transient nature of α S (Dettmer et al., 2015b, 2017; Pranke et al., 2011; Harada et al., 2009). Six or seven repeats of a K_LKEGV or KTK_LEV or KTK_LGV mutant can destabilize native tetramers/multimers in neurons and presumably lead to the accumulation of helical monomeric α S at membranes and perhaps some unfolded cytosolic α S. These mutants remained monomeric when tested by DSG crosslinking and were highly enriched in PBS-insoluble fractions that required Triton-X 100 to solubilize membranes (Dettmer et al., 2015b). Beyond such artificially engineered α S, an amplification of the E46K fPD-linked mutant (i.e., KTK_LGV in repeat 4) in the two adjacent repeat motifs strongly reduces tetramers/multimer levels, as suggested by intact cell-crosslinking and YFP-fluorescent-protein complementation assays. α S ‘3K’ also accumulates in PBS-insoluble fractions (Dettmer et al., 2015a, 2017). In addition, the mutant H50Q was reported to decrease α S solubility 10-fold (Porcari et al., 2015). However, also the membrane-binding deficient, cytosol-enriched fPD variants A30P and G51D cause PD, and it was suggested that they expose their hydrophobic core in solution, thus enabling other α S molecules to bind and aggregate (Ysselstein et al., 2015). A study based on intact-cell crosslinking and YFP complementation concluded that all known fPD-linked α S variants lead to a relative decrease of α S multimers and a gain in aggregation-prone monomers, either in the cytosol or at membranes, depending on the specific mutants (Dettmer, 2018; Dettmer et al., 2015a). In short,

certain regions of α S as well as specific residues have been shown to play a role in either increasing or decreasing binding affinities to lipid bilayers through electrostatic or Van der Waals interactions; increasing α S dwell-time either in the cytosol or at membranes both seem to decrease multimerization, with negative consequences on cell health, as evidenced by the α S fPD-causing variants.

Lastly, post-translational modifications add nuance to α S proteostasis. α S phosphorylation is of particular interest because 90% of aggregated α S present in Lewy bodies were reported to be phosphorylated at serine 129 (pS129) (Fujiwara et al., 2002), implying that this specific phosphorylation event is connected to pathology (Fig. 1B). In addition to the largely insoluble Lewy bodies, however, soluble pS129 α S has been found in CSF samples from PD patients and even controls e.g., Wang et al. (2012). Growing evidence also indicates that Lewy bodies can contain large amounts of pS129-positive α S without being fibrillary, e.g., a very recent study by Shahmoradian et al. (2019). The interplay between pS129 and α S tetramerization/multimerization has not yet been studied. Moreover, it has been proposed that pS129 may actually be a neuroprotective mechanism to accelerate the clearance of aggregated α S (Machiya et al., 2010; Oueslati, 2016). This may be achieved at least with the aid of PLK-2 (Oueslati et al., 2013). Still other groups have concluded that rather than neurotoxic or neuroprotective roles for pS129, it serves a normal regulatory function in α S turnover (Tenreiro et al., 2014) and even in controlling gene expression (Pinho et al., 2019). In short, whether pS129 unequivocally indicates pathology under all circumstances is unclear. The trigger for pS129, whether certain kinases phosphorylate only when α S interacts with membranes, or whether a 'master kinase' exists may all be important questions, the answers to which might further reveal whether pS129 plays multiple roles in contributing to synucleinopathy.

3. Tau

3.1. Tau in health and disease

One of the hallmarks of AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), Pick's disease, and other neurodegenerative diseases collectively called tauopathies are the so-called neurofibrillary tangles (NFTs), which consist mainly of aggregated tau protein (Grundke-Iqbal et al., 1986a; Kosik et al., 1986; Wood et al., 1986; Wolozin et al., 1986). There are numerous efforts to target tau with the hope of slowing disease progression and subsequent cognitive decline. In the case of AD, this is done in addition to targeting amyloid beta, the other, more upstream neuropathological hallmark of AD (Hardy and Selkoe, 2002). Interestingly, the level of dementia in AD patients and AD animal models may correlate well with tau lesions (Braak and Braak, 1996; Nelson et al., 2012; Golde, 2014) – one of several reasons to thoroughly examine the therapeutic potential of tau. Since the discovery of tau from porcine brain MT fractions in 1975 (Weingarten et al., 1975) and its identification as the main NFT component (Grundke-Iqbal et al., 1986a; Kosik et al., 1986; Wood et al., 1986; Wolozin et al., 1986), major advances have been made in understanding the biology of tau, especially focusing on its aggregation and hyper-phosphorylation in tauopathies (Weingarten et al., 1975; Lee et al., 2001).

Tau is an MT-associated protein (MAP) that may be involved in regulating MT stability (see 3.2-3.4.). The tau protein exists in six isoforms ranging in size from 352 to 441 amino acids as a result of alternative splicing of exons (Goedert et al., 1989). The isoforms are marked by the presence or absence of exons 2, 3, and 10 and are regulated based on the stage of development of the brain, though their specific function is not known (Kosik et al., 1989). The isoforms are named based on how many MT binding repeats (R) are expressed, with the 3R isoform having three MT binding repeats and the 4R isoform four binding repeats (Lee et al., 2001). The 3R isoform is expressed mainly during the early development stage of the brain and the 4R

isoform is expressed later in adulthood (Goedert et al., 1989; Kosik et al., 1989). Most of what we know about tau originates from its function in neuronal cells. Besides its neuronal expression, tau was found to be expressed in non-neuronal tissues such as liver, muscle, kidney, and even cancer cell lines (Rouzier et al., 2005; Kenner et al., 1994). Tau's characterization as an 'intrinsically disordered' protein in solution, while having numerous (proposed) functions within the cell, challenged the thought that proteins have to be pre-folded to exhibit specific functions in a cell (Goedert et al., 1991; Lee and Trojanowski, 1992).

3.2. Tau transiently binds to MTs

As one of the three major component of the cytoskeleton, MTs control the formation of mitotic spindles, cilia, and flagella, and play an important role in cell motility and polarity (Viswanadha et al., 2017; Barlan and Gelfand, 2017). MTs are built from α - and β -tubulin monomers into long, cylindrical, hollow-shaped protofilaments. MTs undergo dynamic changes between growth and shortening known as dynamic instability (Mitchison and Kirschner, 1984). Individual MT polymers elongate by the addition of GTP-tubulin dimers to the end of the MT and shrink due to the competitive activity of end-binding proteins, preventing new tubulin dimers to bind (Akhmanova and Steinmetz, 2008; Akhmanova and Steinmetz, 2015). A group of proteins known as MAPs binds to and promotes the assembly and stabilization of MTs. Tau is a MAP that transiently interacts with MTs to regulate their dynamics and spatial organization. In addition, tau is believed to stabilize MTs in axons which serve as 'roads' for transport within the cell (Hirokawa and Takemura, 2005). There are many proposed mechanisms for the MT-associated function of tau (Choi et al., 2009; Butner and Kirschner, 1991; Santarella et al., 2004). Several lines of investigation substantiate that tau bridges linear rows of tubulin dimers, by binding to several protofilaments via its MT-binding repeats (Al-Bassam et al., 2002; Kar et al., 2003). Others have shown that tau stabilizes MTs by bridging the interfaces of tubulin heterodimers (Kadavath et al., 2015a). Recent findings, however, suggest that tau may not stabilize axonal MTs at all, but rather modifies the biology of MTs by enabling them to have long labile domains (Qiang et al., 2018; Baas and Qiang, 2019). Various techniques such as protein biochemistry and NMR have been used to delineate the physical and structural basis of the transient tau-MT interaction leading to different hypotheses/models about the interplay between these two binding partners.

It has been suggested that a dynamic equilibrium between free tau and tau bound to MTs is dictated by tau phosphorylation and de-phosphorylation cycles (Ballatore et al., 2007; Biernat et al., 1993; Scott et al., 1993). Phosphorylation sites such as Ser262, Ser365, Ser205, and Thr231 are typically considered to reduce the strength of the interaction between tau and MTs when phosphorylated (Ballatore et al., 2007). Tau phosphorylation was proposed to alter its conformation and affinity to MTs, leading to a detachment from MTs (Jho et al., 2010; Fischer et al., 2009). In line with this idea, dysregulation of certain kinases has been proposed to perturb or even eliminate tau's MT binding in models of tauopathies (Trinczek et al., 1995; Sun and Gamblin, 2009; Leger et al., 1997). While tau hyper-phosphorylation is certainly a hallmark of tauopathies, recent studies challenge the view that phosphorylation cycles are the key mechanism underlying transient (instead of stable) tau-MT interaction. In various binding and decay assays, it was shown that tau may be bound on each MT filament for only ~40 ms (Janning et al., 2014). This dwell-time is ~100 times shorter than previously reported (Konzack et al., 2007) and too short for regulation by kinases: the average catalytic ability of a kinase is approximately 10 interactions per second (Newton, 1995). Hence, a 'kiss-and-hop mechanism' of regulating tau-MT interaction was proposed (Janning et al., 2014). Rather than a phosphorylation/de-phosphorylation mechanism of controlling the transient MT-tau interaction, the authors suggest that tau may 'hop' between MTs in an undirected manner. Despite its high




Fig. 3. Transient cellular behavior of tau. A, Physiological situation: Coming off the ribosome, tau is soluble, unfolded, and monomeric. Upon binding to MTs, tau adopts a different fold, but almost immediately becomes soluble again. Tau phosphorylation may contribute to regulating the transient tau-MT interaction. B, Pathological situation (pathological states are in red): perturbed cellular tau homeostasis is characterized by tau hyper-phosphorylation, lack of tau-MT interaction, disintegration of MTs and the formation of proteinaceous tau aggregates. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

mobility, it was postulated that tau can shift the tubulin equilibrium toward polymerization: the short interaction time between tau and MTs was proposed to suppress the natural dissociation of tubulin dimers. Janning et al. further speculate that the rapid kiss-and-hop interaction that they observe may explain why tau, although binding to MTs, does not interfere with axonal transport. It is worth noting that the ‘kiss and hop’ model was developed in PC12 cells which do not express axonal components. Therefore, the distance between two MTs is ~ 70 nm instead of the average ~ 20 nm for MT-MT interactions (Jacobs and Stevens, 1986). It is conceivable that details of the protein conformation and the effect of phosphorylation amongst others are model-dependent (Narayanan et al., 2010). While probably not regulating the binding/unbinding cycles per se, its exact phosphorylation state is still expected to contribute to tau's overall MT binding affinity (see Fig. 3B). Reduced MT binding may in turn cause accumulation in the cytosol and aggregation. Fig. 3A summarizes several aspects discussed in this paragraph and emphasizes the proposed kiss-and-hop mechanism of the tau-MT interaction (Janning et al., 2014). Fig. 3B illustrates potential patho-mechanisms of AD, FTD, and other tauopathies in the context of impaired tau-MT interaction.

3.3. Lack of strong evidence for physiological multimeric forms of tau

The tau literature does not provide ample evidence for the existence

of native tau higher-order assemblies. One study (Rosenberg et al., 2008) employed a surface force apparatus to determine the force profile for each of six tau isoforms physisorbed through self-assembly from solution to negatively charged mica surfaces. The authors interpreted their data as incompatible with tau acting on MTs as a monomer and speculated that two tau molecules may associate in an antiparallel configuration. This structure was suggested to be held together by an electrostatic ‘zipper’ of complementary salt bridges composed of the N-terminal and central regions of each tau monomer, with the C-terminal MT-binding regions extending outward from each end of the dimeric backbone. This tau dimer would then determine the length and strength of the linker holding two MTs together and to be the fundamental structural unit of tau, underlying both its normal and pathological action. Independent confirmation of such a mechanism is lacking.

3.4. Molecular determinants of the transient nature of tau

Tau is typically characterized as consisting of an N-terminal-, a proline-rich, an MT-binding domain (MBD), and a C-terminal domain (Fig. 4). As is evident from their name, the MT-binding domains are important for MT interactions (Goedert et al., 1989; Mandelkow et al., 1996). Each isoform of tau has three to four repeats (‘R-repeats’) located in the C-terminus (Goedert and Jakes, 1990). Using synthetic tau fragments, it has been shown that these repeats form MT-binding units




Fig. 4. Molecular determinants of the transient nature of tau. Top left: the 441-aa sequence of human wildtype '4R' tau contains 4 semi-conserved 31 or 32-aa 'R repeats', plus proline-rich, N-terminal and C-terminal domains. Bottom left: color-coded schematic of the 4 R repeats. Blue indicates basic (light blue: histidine), red: acidic, purple: polar uncharged, black: non-polar, green: proline residues. Right: Color-coded schematic of R repeat 1 bound to MTs via 3 tubulin subunits (2 β , 1 α). The proposed structure is neither unfolded nor helically or β -sheet folded. Instead, it is characterized as 'extended'. The exact molecular basis for a highly transient, instead of a strong binding to MTs will require further research. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

(Himmler et al., 1989; Lee et al., 1989). Positively charged repeat sequences of the MBD were proposed to interact with negatively charged residues in tubulin and hence to facilitate the tau-tubulin interaction (Kar et al., 2003; Jho et al., 2010). Recent studies based on NMR (Kadavath et al., 2015b) and cryo-EM (Kellogg et al., 2018) provide detailed insight into a complex mode of interaction. Both studies reiterate the previous notion that MT-bound tau does not become helical - in contrast to vesicle-bound α S that forms membrane-induced amphipathic 11/3 helices. Instead, tau adopts an 'extended' secondary structure, a state that is both different from unfolded and from helically or beta-sheet folded. In the extended structure, each of tau's R-repeats was observed to span both intra- and inter-dimer interfaces, centered on α -tubulin and connecting three tubulin monomers (Fig. 4). In each individual interaction site, key tau residues engage in specific interactions with key MT residues. Examples from the cryo-EM study (Kellogg et al., 2018) are: Ser258 and Ser262 in tau form hydrogen bonds with α -tubulin Glu434. Tau's conserved Lys259 interacts with an acidic α -tubulin patch formed by Asp424, Glu420, and Glu423. Ile260 is buried within a hydrophobic pocket formed by α -tubulin's Ile265, Val435, and Tyr262 at the inter-dimer interface. Lys267 may be positioned to interact with the acidic α -tubulin C-terminal tail. The universally conserved Ser262 was proposed to be critically involved in tight contacts with tubulin near a polymerization interface. The new structure thus now offers a detailed explanation for how Ser262 phosphorylation may disrupt tau-tubulin interactions.

What these new studies leave open, however, is why tau binding to MTs is actually dynamic, and tau's dwell-time on MTs is so short. Importantly, the studies should not be misinterpreted as evidence for the presence of stable MT-tau assemblies within cells. The authors do not point to specific amino acids that are 'sub-optimal' for achieving energetic minima (such as the central threonine in the hydrophobic half of α S membrane-associated helices; see Fig. 2). The rapid switch of tau between soluble and MT-bound tau suggests that the energetic minimum of the soluble unfolded state is similar to that of the MT-bound state(s). Though it may contribute to it, Ser262 phosphorylation is not expected to be the sole reason for tau's dynamic behavior, for reasons discussed in Section 3.2.

While the 2015 and 2018 structural studies mainly focused on the

R-repeats, the proline-rich regions in tau are also believed to influence the tau-MT interaction (Lewis et al., 1989; Kanai et al., 1992). The proline regions line the repeat domain of tau and may initiate the formation of the tau-MT interaction by binding to the MT-binding repeats of tubulin, a 'green light' to trigger tau-MT interactions (Butner and Kirschner, 1991; Gustke et al., 1994). Notably, there are many phosphorylation sites on the proline-rich region which may affect interactions with other proteins as well as tau-MT interactions (Steinhilb et al., 2007; Gong et al., 2005). Mutagenesis studies on human tau isoforms revealed that loss of the proline-rich domains reduces MT binding (Kanai et al., 1992). Tau mutants with a deletion of the repeat domain, but with an intact proline-rich domain, were found to still bind to MTs (Gustke et al., 1994; Preuss et al., 1997). Combining the proline-rich regions with the adjacent repeat regions increased the binding affinity of tau 10-fold compared to mutants lacking the proline-rich region (Goode et al., 1997). Taken together, the data show that the proline-rich domain and the repeat regions in tau synergistically promote its MT binding. Accordingly, Mandelkow and colleagues proposed the 'jaws' model of MT-tau interaction to explain these observations (Preuss et al., 1997; Mukrasch et al., 2007). Mutants of tau with deletions or multiplications of different domains were generated and tested for tau-MT interactions in cells. The authors found evidence for the binding of tau with MTs in the absence of the repeat regions. However, these mutants were unable to stabilize MTs. Increasing the number of repeats in the repeat region enhanced the interaction and effect of tau on MTs. On the other hand, mutants with deletion of the proline-rich regions flanking the repeat regions showed only low affinity to MTs and did not induce reorganization of the MTs. The authors concluded that the proline-rich regions flanking the binding repeats serve as targeting domains to position tau on the MTs and that the repeat domain act as the primary interacting domains, hence the 'jaw' model of tau-MT interaction (Preuss et al., 1997). According to the authors, stabilization of MTs is only achieved if both domains of tau act together.

4. Therapeutic intervention via correcting transient behaviors of α S and tau?

The transient behavior and context-specific folding of α S and tau is

not a contradiction to their frequent characterization as ‘intrinsically disordered proteins’ because this term can simply be interpreted as lack of a sole and fixed three-dimensional structure. However, all current major protein classes considered ‘druggable’ are stably folded in their native states. Proteins like α S and tau on the contrary seem to exist as heterogeneous conformational ensembles, which renders them unsuitable for standard rational drug design approaches (Joshi and Vendruscolo, 2015). Nonetheless, several different small molecule strategies are currently under investigation, including: (1) stabilizing the proteins in their natively disordered states, (2) inhibiting interactions with binding partners, and (3) inducing allosteric inhibition (Joshi and Vendruscolo, 2015).

In agreement with scenario (1), Collier et al. (2017) proposed that the tricyclic antidepressant compound nortriptyline can inhibit the aggregation of α S by directly binding to the soluble, monomeric form. The authors further suggested that nortriptyline-mediated ‘re-configuration of the monomer’ can inhibit the formation of toxic conformations of the protein. Similarly, a recent study reported that stabilizing α S monomers with the polyphenol Oleuropein aglycone (OleA) reduced the likelihood for α S to aggregate into toxic molecules (Palazzi et al., 2018) (see Singh et al., 2017 review for further comment on phenol-based strategies). More in line with scenario (2), Perni et al., 2017 demonstrated that squalamine (a natural product with proposed anticancer and antiviral activity that can be extracted from shark liver) can prevent α S aggregation by displacing α S from the surfaces of vesicles. This was suggested to block a first, membrane-assisted, step in the α S aggregation process. The same group then reported that the related compound trodusquemine not only inhibits α S-membrane interactions, but also blocks the fibril-dependent secondary pathways in the aggregation reaction, thereby effectively suppressing the toxicity of α S oligomers in neuronal cells (Perni et al., 2018). However, other groups had suggested that pharmacological stabilization of monomeric α S in its helical form at membranes may inhibit pathogenic misfolding and aggregation (Fonseca-Ornelas et al., 2014). Both approaches could in theory also turn out to be problematic since α S monomers both in membrane-associated (Galvagnion et al., 2015) and soluble conformations (Conway et al., 1998, 2000; Burré et al., 2015) have been reported to be aggregation-prone. Thus, another attractive option of preventing α S aggregation would be stabilizing native multimeric/tetrameric states of α S that have been reported to be aggregation-resistant (Iljina et al., 2016; Bartels et al., 2011). An example of the direct stabilization of a tetrameric protein via a small molecule, thereby preventing amyloidosis, is the drug tafamidis, which stabilizes transthyretin (Johnson et al., 2012). While the design of direct stabilizers of α S tetramers may depend on the successful generation of α S tetramer/multimer high-resolution structural data, it was recently shown that stabilizing native α S assembly can be achieved in an indirect fashion: the inhibition of stearoyl-CoA-desaturase (SCD) can increase α S multimer:monomer ratios in the multimerization-deficient familial-PD-linked mutant E46K (Fanning et al., 2018). The exact mechanism is not clear, but it seems likely that blocking the SCD-catalyzed production of oleic acid (18:1) causes a reduced occurrence of this fatty acid in membrane lipids, leading to higher levels of saturated fatty acids. A higher degree of saturation has been reported to interfere with α S-membrane interaction because ‘membrane defects’ that favor α S binding are less likely to occur (Nuscher et al., 2004). Thus, the correction of excess α S E46K membrane binding and the correction of E46K’s lack of multimerization seem to go hand in hand. The target SCD was confirmed in a different study that was based on α S (yeast) toxicity (Vincent et al., 2018).

In the case of tau, a recent study investigated the structural basis of small molecule druggability of native tau monomers (Kiss et al., 2018). As an example, the authors showed that methylene blue binds to monomeric full-length tau selectively with high affinity ($K_d = 86.6$ nM). The authors interpret their study as evidence that tau can be a viable drug target for small molecules that bind to monomeric tau and influence the way in which the protein interacts among itself

and with other proteins (Kiss et al., 2018). Clinical trials based on methylene blue have thus far turned out to be rather disappointing (Wischnik et al., 2015; Gauthier et al., 2016; Wilcock et al., 2018). Authors’ claims of some efficacy after a post-hoc subgroup secondary analysis have been controversial (Medina, 2018). A 2013 review (Bulic et al., 2013) lists several classes of potential inhibitors/modulators of tau aggregation such as polyphenols, rhodanines, phenyl-thiazolylhydrazide, N-phenylamines, benzothiazoles, and aminothienopyridazines. Only few of these structures are expected to actually bind to and stabilize monomeric soluble tau; most inhibitors/modulators likely redirect the self-assembly toward ‘off-pathway’ oligomeric forms (Bulic et al., 2013). In light of the topic of this review, such compounds are not considered modulators of normal dynamic behavior of tau. Moreover, many putative aggregation inhibitors have demonstrated to be potent in *in vitro* assays, but evidence of inhibiting tau aggregation *in vivo* and, even more importantly, cognitive improvement is still lacking (Medina, 2018). It is also worth mentioning that the specificity of tau aggregation inhibitors, including methylene blue, is limited, and pleiotropic effects can be expected (Medina, 2018). Harnessing the hyper-phosphorylation of aggregated tau (Grundke-Iqbal et al., 1986b) for therapy has been considered a viable approach for a long time. However, tau phosphorylation cannot solely be considered a pathological event because the protein’s transient binding to MTs is likely to be regulated at least in part via phosphorylation as well (see 3.3) (Lindwall and Cole, 1984). The kinases and phosphatases that have been demonstrated to be involved in tau phosphorylation comprise GSK3 β , Cdk5, and p25 (Tell and Hilgeroth, 2013; Shukla et al., 2012). Interfering with tau phosphorylation promises to affect protein homeostasis upstream of proteinaceous aggregation and remains a valuable strategy. However, the exact regulation as well as physiological and/or pathological significance of tau phosphorylation at all its different phosphorylation sites remain questions to be answered.

Lastly, while modifying the composition of the vesicles that α S binds to (e.g., via SCD inhibition) has emerged only recently as a new potential strategy for treating synucleinopathies (Fanning et al., 2018; Vincent et al., 2018), tubulin-stabilizing compounds have already been tested in clinical trials (Morimoto et al., 2013; Boxer et al., 2014), albeit unsuccessfully in phase III (Boxer et al., 2014). MT imbalance is typically considered a downstream effect of tau dyshomeostasis. The interplay between α S and fatty acids/lipids/vesicles, however, may be more complicated. For example, a previous study demonstrated that expressing α S alters fatty acid composition of dopaminergic neurons in a way that reflects alterations in human brains with synucleinopathies (Sharon et al., 2003). Genetic evidence, on the other hand, suggests that impaired glucocerebrosidase activity may be upstream of α S dyshomeostasis in PD pathogenesis (Aharon-Peretz et al., 2004; Goker-Alpan et al., 2006). Mazzulli et al. proposed a ‘bidirectional pathogenic loop’ between glucocerebrosidase and α S (Mazzulli et al., 2011). Other lipid-related genes that emerged from GWAS as PD risk factors comprise a diacylglycerol kinase (DGKQ), which controls cellular diglyceride content (Simon-Sanchez et al., 2009; Simon-Sanchez et al., 2011; Chen et al., 2013; Nalls et al., 2014; Zhu et al., 2017), and fatty acid elongase 7, a determinant of acyl-chain length and hence lipid composition/membrane fluidity (Chang et al., 2017). Both indicate that changes in lipid metabolism can be upstream of α S dyshomeostasis (which does not exclude additional effects on lipids downstream of α S). In turn, modifying cellular lipid composition could indeed help keep cellular α S folding homeostasis intact or correct it back to normal. A similar approach for correcting tau homeostasis via modification of MT biology may be less evident from genetics or the literature in general.

It is also important to note that in both tauopathies and synucleinopathies the pathway toward fibrillary assembly may be quite different from one disease to another. As far as the endpoints are concerned, there is growing evidence for disease-specific aggregate formation. For example, the single protofilaments with an elongated and loosely arranged structure found in Pick’s Disease are markedly

different from the compact bundles of C-shaped paired helical tau filaments found in AD (Goedert et al., 2017; Fitzpatrick et al., 2017). Similarly, PD, DLB, and MSA have been reported to be characterized by distinct α S aggregate 'strains' that exhibit different 'seeding' characteristics (Peelaerts et al., 2015, 2018; Yamasaki et al., 2019), and the notion of non-fibrillar, membranous α S aggregation (Shahmoradian et al., 2019) adds further complexity. These differences in advanced pathology may point at differences in disease initiation. As a consequence, drugs targeting certain transient forms within tau and α S dynamic equilibria could be disease-specific and inefficient toward another assembly pathway.

Acknowledgments

We thank Dennis Selkoe, Nagendran Ramalingam, Thibaut Imberdis, Saranna Fanning, Elizabeth Terry-Kantor, Luis Fonseca-Ornelas, and Arati Tripathi (BWH/Harvard Medical School) as well as Tim Bartels and Tong Guo (University College London) for discussions and critical revision of the manuscript. UD's research is funded by NIH (USA) grant NS099328.

References

- Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D., Rosenthal, A., 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. *Neuron* 25, 239–252.
- Aharon-Peretz, J., Rosenbaum, H., Gershoni-Baruch, R., 2004. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. *N. Engl. J. Med.* 351, 1972–1977. <https://doi.org/10.1056/NEJMoa033277>.
- Akhmanova, A., Steinmetz, M.O., 2008. Tracking the ends: a dynamic protein network controls the fate of microtubule tips. *Nat. Rev. Mol. Cell Biol.* 9, 309–322. <https://doi.org/10.1038/nrm2369>.
- Akhmanova, A., Steinmetz, M.O., 2015. Control of microtubule organization and dynamics: two ends in the limelight. *Nat. Rev. Mol. Cell Biol.* 16, 711–726. <https://doi.org/10.1038/nrm4084>.
- Al-Bassam, J., Ozer, R.S., Safer, D., Halpain, S., Milligan, R.A., 2002. MAP2 and tau bind longitudinally along the outer ridges of microtubule protofilaments. *J. Cell Biol.* 157, 1187–1196. <https://doi.org/10.1083/jcb.200201048>.
- Alderson, T.R., Bax, A., 2016. Parkinson's disease: disorder in the court. *Nature*. <https://doi.org/10.1038/nature16871>.
- Alderson, T.R., Markley, J.L., 2013. Biophysical characterization of α -synuclein and its controversial structure. *Intrinsically Disord. Proteins* 1, e26255. <https://doi.org/10.4161/idp.26255>.
- Almanoz-Gil, L., Persson, E., Lindström, V., Ingelsson, M., Erlandsson, A., Bergström, J., 2018. Situ proximity ligation assay reveals co-localization of alpha-synuclein and snare proteins in murine primary neurons. *Front. Neurol.* 9, 180. <https://doi.org/10.3389/fneur.2018.00180>.
- Baas, P.W., Qiang, L., 2019. Tau: it's not what you think. *Trends Cell Biol.* <https://doi.org/10.1016/j.tcb.2019.02.007>.
- Ballatore, C., Lee, V.M., Trojanowski, J.Q., 2007. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. *Nat. Rev. Neurosci.* 8, 663–672. <https://doi.org/10.1038/nrn2194>.
- Barlan, K., Gelfand, V.I., 2017. Microtubule-based transport and the distribution, tethering, and organization of organelles. *Cold Spring Harb Perspect Biol* 9. <https://doi.org/10.1101/cshperspect.a025817>.
- Bartels, T., Choi, J.G., Selkoe, D.J., 2011. α -Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. *Nature* 477, 107–110. <https://doi.org/10.1038/nature10324>.
- Bendor, J.T., Logan, T.P., Edwards, R.H., 2013. The function of α -synuclein. *Neuron* 79, 1044–1066. <https://doi.org/10.1016/j.neuron.2013.09.004>.
- Berrocal, R., Vasquez, V., Rao Krs, S., Gadad, B.S., Rao, K.S., 2015. α -Synuclein misfolding versus aggregation relevance to parkinson's disease: critical assessment and modeling. *Mol. Neurobiol.* 51, 1417–1431. <https://doi.org/10.1007/s12035-014-8818-2>.
- Biernat, J., Gustke, N., Drewes, G., Mandelkow, E.M., Mandelkow, E., 1993. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. *Neuron* 11, 153–163.
- Binolfi, A., Theillet, F.-X., Selenko, P., 2012. Bacterial in-cell NMR of human α -synuclein: a disordered monomer by nature? *Biochem. Soc. Trans.* 40, 950–954. <https://doi.org/10.1042/BST20120096>.
- Boxer, A.L., Lang, A.E., Grossman, M., Knopman, D.S., Miller, B.L., Schneider, L.S., Doody, R.S., Lees, A., Golbe, L.I., Williams, D.R., Corvol, J.-C., Ludolph, A., Burn, D., Lorenz, S., Litvan, I., Roberson, E.D., Höglinger, G.U., Koestler, M., Jack, C.R., Van Deerlin, V., Randolph, C., Lobach, I.V., Heuer, H.W., Gozes, I., Parker, L., Whitaker, S., Hirman, J., Stewart, A.J., Gold, M., Morimoto, B.H., 2014. AL-108-231 investigators, davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. *Lancet Neurol.* 13, 676–685. [https://doi.org/10.1016/S1474-4422\(14\)70088-2](https://doi.org/10.1016/S1474-4422(14)70088-2).
- Braak, H., Braak, E., 1996. Evolution of the neuropathology of Alzheimer's disease. *Acta Neurol. Scand. Suppl.* 165, 3–12.
- Brucale, M., Sandal, M., Di Maio, S., Rampioni, A., Tessari, I., Tosatto, L., Bisaglia, M., Bubacco, L., Samori, B., 2009. Pathogenic mutations shift the equilibria of alpha-synuclein single molecules towards structured conformers. *ChemBiochem Eur. J. Chem. Biol.* 10, 176–183. <https://doi.org/10.1002/cbic.200800581>.
- Bulic, B., Pickhardt, M., Mandelkow, E., 2013. Progress and developments in tau aggregation inhibitors for Alzheimer disease. *J. Med. Chem.* 56, 4135–4155. <https://doi.org/10.1021/jm3017317>.
- Burré, J., 2015. The synaptic function of α -synuclein. *J. Park. Dis.* 5, 699–713. <https://doi.org/10.3233/JPD-150642>.
- Burré, J., Sharma, M., Südhof, T.C., 2014. α -Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. *Proc. Natl. Acad. Sci.* 111, E4274–E4283. <https://doi.org/10.1073/pnas.1416598111>.
- Burré, J., Sharma, M., Südhof, T.C., 2015. Definition of a molecular pathway mediating α -synuclein neurotoxicity. *J. Neurosci.* 35, 5221–5232. <https://doi.org/10.1523/JNEUROSCI.4650-14.2015>.
- Burré, J., Vivona, S., Diao, J., Sharma, M., Brunger, A.T., Südhof, T.C., 2013. Properties of native brain α -synuclein. *Nature* 498, E4–E6. <https://doi.org/10.1038/nature12125>.
- Busch, D.J., Oliphint, P.A., Walsh, R.B., Banks, S.M.L., Woods, W.S., George, J.M., Morgan, J.R., 2014. Acute increase of α -synuclein inhibits synaptic vesicle recycling evoked during intense stimulation. *Mol. Biol. Cell* 25, 3926–3941. <https://doi.org/10.1091/mbc.E14-02-0708>.
- Butner, K.A., Kirschner, M.W., 1991. Tau protein binds to microtubules through a flexible array of distributed weak sites. *J. Cell Biol.* 115, 717–730.
- Cai, W., Feng, D., Schwarzschild, M.A., McLean, P.J., Chen, X., 2018. Bimolecular fluorescence complementation of alpha-synuclein demonstrates its oligomerization with dopaminergic phenotype in mice. *EBioMedicine* 29, 13–22. <https://doi.org/10.1016/j.ebiom.2018.01.035>.
- Chandra, S., Chen, X., Rizo, J., Jahn, R., Südhof, T.C., 2003. A broken alpha-helix in folded alpha-Synuclein. *J. Biol. Chem.* 278, 15313–15318. <https://doi.org/10.1074/jbc.M213128200>.
- Chandra, S., Fornai, F., Kwon, H.-B., Yazdani, U., Atasoy, D., Liu, X., Hammer, R.E., Battaglia, G., German, D.C., Castillo, P.E., Südhof, T.C., 2004. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. *Proc. Natl. Acad. Sci. U. S. A.* 101, 14966–14971. <https://doi.org/10.1073/pnas.0406283101>.
- Chang, D., Nalls, M.A., Hallgrímsson, I.B., Hunkapiller, J., van der Brug, M., Cai, F., International Parkinson's Disease Genomics Consortium, 23andMe Research Team, Kerchner, G.A., Ayalon, G., Bingol, B., Sheng, M., Hinds, D., Behrens, T.W., Singleton, A.B., Bhargale, T.R., Graham, R.R., 2017. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nat. Genet.* 49, 1511–1516. <https://doi.org/10.1038/ng.3955>.
- Chen, Y.P., Song, W., Huang, R., Chen, K., Zhao, B., Li, J., Yang, Y., Shang, H.F., 2013. GAK rs1564282 and DGKQ rs11248060 increase the risk for Parkinson's disease in a Chinese population. *J. Clin. Neurosci.* 20, 880–883. <https://doi.org/10.1016/j.jocn.2012.07.011>.
- Cheng, C.-Y., Varkey, J., Ambrosio, M.R., Langen, R., Han, S., 2013. Hydration dynamics as an intrinsic ruler for refining protein structure at lipid membrane interfaces. *Proc. Natl. Acad. Sci. U. S. A.* 110, 16838–16843. <https://doi.org/10.1073/pnas.1307678110>.
- Choi, M.C., Raviv, U., Miller, H.P., Gaylord, M.R., Kiris, E., Ventimiglia, D., Needleman, D.J., Kim, M.W., Wilson, L., Feinstein, S.C., Safinya, C.R., 2009. Human microtubule-associated-protein tau regulates the number of protofilaments in microtubules: a synchrotron x-ray scattering study. *Biophys. J.* 97, 519–527. <https://doi.org/10.1016/j.bpj.2009.04.047>.
- Collier, T.J., Srivastava, K.R., Justman, C., Grammatopoulos, T., Hutter-Paier, B., Prokesch, M., Hvas, D., Rochet, J.-C., Liu, F., Jock, K., de Oliveira, P., Stirtz, G.L., Dettmer, U., Sortwell, C.E., Feany, M.B., Lansbury, P., Lapidus, L., Paumier, K.L., 2017. Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. *Neurobiol. Dis.* 106, 191–204. <https://doi.org/10.1016/j.nbd.2017.07.007>.
- Conway, K.A., Harper, J.D., Lansbury, P.T., 1998. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. *Nat. Med.* 4, 1318–1320. <https://doi.org/10.1038/3311>.
- Conway, K.A., Harper, J.D., Lansbury, P.T., 2000. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to parkinson's disease are typical amyloid. *Biochem. Mosc.* 39, 2552–2563.
- Cremades, N., Chen, S.W., Dobson, C.M., 2017. Structural characteristics of α -synuclein oligomers. *Int. Rev. Cell Mol. Biol.* 329, 79–143. <https://doi.org/10.1016/bs.ircmb.2016.08.010>.
- Davidson, W.S., Jonas, A., Clayton, D.F., George, J.M., 1998. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. *J. Biol. Chem.* 273, 9443–9449.
- Dettmer, U., 2018. Rationally designed variants of α -synuclein illuminate its in vivo structural properties in health and disease. *Front. Neurosci.* 12, 623. <https://doi.org/10.3389/fnins.2018.00623>.
- Dettmer, U., Newman, A.J., Luth, E.S., Bartels, T., Selkoe, D., 2013. In vivo cross-linking reveals principally oligomeric forms of α -synuclein and β -synuclein in neurons and non-neural cells. *J. Biol. Chem.* 288, 6371–6385. <https://doi.org/10.1074/jbc.M112.403311>.
- Dettmer, U., Newman, A.J., Soldner, F., Luth, E.S., Kim, N.C., von Saucken, V.E., Sanderson, J.B., Jaenisch, R., Bartels, T., Selkoe, D., 2015a. Parkinson-causing α -synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. *Nat. Commun.* 6. <https://doi.org/10.1038/ncomms8314>.
- Dettmer, U., Newman, A.J., von Saucken, V.E., Bartels, T., Selkoe, D., 2015b. KTKEGV

- repeat motifs are key mediators of normal α -synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity. *Proc. Natl. Acad. Sci. U. S. A.* 112, 9596–9601. <https://doi.org/10.1073/pnas.1505953112>.
- Dettmer, U., Ramalingam, N., von Saucken, V.E., Kim, T.-E., Newman, A.J., Terry-Kantor, E., Nuber, S., Ericsson, M., Fanning, S., Bartels, T., Lindquist, S., Levy, O.A., Selkoe, D., 2017. Loss of native α -synuclein multimerization by strategically mutating its amphipathic helix causes abnormal vesicle interactions in neuronal cells. *Hum. Mol. Genet.* 26, 3466–3481. <https://doi.org/10.1093/hmg/ddx227>.
- Dettmer, U., Selkoe, D., Bartels, T., 2016. New insights into cellular α -synuclein homeostasis in health and disease. *Curr. Opin. Neurobiol.* 36, 15–22. <https://doi.org/10.1016/j.conb.2015.07.007>.
- Dimant, H., Kalia, S.K., Kalia, L.V., Zhu, L.N., Kibuuka, L., Ebrahimi-Fakhari, D., McFarland, N.R., Fan, Z., Hyman, B.T., McLean, P.J., 2013. Direct detection of alpha synuclein oligomers in vivo. *Acta Neuropathol. Commun.* 1, 6. <https://doi.org/10.1186/2051-5960-1-6>.
- Eliezer, D., Kutluay, E., Bussell, R., Browne, G., 2001. Conformational properties of alpha-synuclein in its free and lipid-associated states. *J. Mol. Biol.* 307, 1061–1073. <https://doi.org/10.1006/jmbi.2001.4538>.
- Fakhree, M.A.A., Zijlstra, N., Raiss, C.C., Siero, C.J., Grabmayr, H., Bausch, A.R., Blum, C., Claessens, M.M.A.E., 2016. The number of α -synuclein proteins per vesicle gives insights into its physiological function. *Sci. Rep.* 6, 30658. <https://doi.org/10.1038/srep30658>.
- Fanning, S., Haque, A., Imberdis, T., Baru, V., Barrasa, M.I., Nuber, S., Termine, D., Ramalingam, N., Ho, G.P.H., Noble, T., Sandoe, J., Lou, Y., Landgraf, D., Freyzo, Y., Newby, G., Soldner, F., Terry-Kantor, E., Kim, T.-E., Hofbauer, H.F., Becuwe, M., Jaenisch, R., Pincus, D., Clish, C.B., Walther, T.C., Farese, R.V., Srinivasan, S., Welte, M.A., Kohlwein, S.D., Dettmer, U., Lindquist, S., Selkoe, D., 2018. Lipidomic analysis of α -Synuclein neurotoxicity identifies stearyl CoA desaturase as a target for parkinson treatment. *Mol. Cell.* <https://doi.org/10.1016/j.molcel.2018.11.028>.
- Fauvet, B., Mbefo, M.K., Fares, M.-B., Desobry, C., Michael, S., Ardah, M.T., Tsika, E., Coune, P., Prudent, M., Lion, N., Eliezer, D., Moore, D.J., Schneider, B., Aebischer, P., El-Agnaf, O.M., Masliah, E., Lashuel, H.A., 2012. α -Synuclein in central nervous system and from erythrocytes, mammalian cells, and *Escherichia coli* exists predominantly as disordered monomer. *J. Biol. Chem.* 287, 15345–15364. <https://doi.org/10.1074/jbc.M111.318949>.
- Fecchio, C., Palazzi, L., Polverino de Laureto, P., Fecchio, C., Palazzi, L., Polverino de Laureto, P., 2018. α -Synuclein and polyunsaturated fatty acids: molecular basis of the interaction and implication in neurodegeneration. *Molecules.* 23, 1531. <https://doi.org/10.3390/molecules23071531>.
- Fischer, D., Mukrasch, M.D., Biernat, J., Bibow, S., Blackledge, M., Griesinger, C., Mandelkow, E., Zweckstetter, M., 2009. Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules. *Biochem. Mosc.* 48, 10047–10055. <https://doi.org/10.1021/bi901090m>.
- Fitzpatrick, A.W.P., Falcon, B., He, S., Murzin, A.G., Murshudov, G., Garringer, H.J., Crowther, R.A., Ghetti, B., Goedert, M., Scheres, S.H.W., 2017. Cryo-EM structures of tau filaments from Alzheimer's disease. *Nature.* 547, 185–190. <https://doi.org/10.1038/nature23002>.
- Fonseca-Ornelas, L., Eisbach, S.E., Paulat, M., Giller, K., Fernández, C.O., Outeiro, T.F., Becker, S., Zweckstetter, M., 2014. Small molecule-mediated stabilization of vesicle-associated helical α -synuclein inhibits pathogenic misfolding and aggregation. *Nat. Commun.* 5, 5857. <https://doi.org/10.1038/ncomms6857>.
- Fortin, D.L., Nemani, V.M., Voglmaier, S.M., Anthony, M.D., Ryan, T.A., Edwards, R.H., 2005. Neural activity controls the synaptic accumulation of alpha-synuclein. *J. Neurosci.* 25, 10913–10921. <https://doi.org/10.1523/JNEUROSCI.2922-05.2005>.
- Fortin, D.L., Troyer, M.D., Nakamura, K., Kubo, S., Anthony, M.D., Edwards, R.H., 2004. Lipid rafts mediate the synaptic localization of alpha-synuclein. *J. Neurosci.* 24, 6715–6723. <https://doi.org/10.1523/JNEUROSCI.1594-04.2004>.
- Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M.S., Shen, J., Takio, K., Iwatsubo, T., 2002. α -Synuclein is phosphorylated in synucleinopathy lesions. *Nat. Cell Biol.* <https://doi.org/10.1038/ncb748>.
- Fusco, G., De Simone, A., Arosio, P., Vendruscolo, M., Veglia, G., Dobson, C.M., 2016. Structural ensembles of membrane-bound α -synuclein reveal the molecular determinants of synaptic vesicle affinity. *Sci. Rep.* 6. <https://doi.org/10.1038/srep27125>.
- Fusco, G., Sanz-Hernandez, M., De Simone, A., 2018. Order and disorder in the physiological membrane binding of α -synuclein. *Curr. Opin. Struct. Biol.* 48, 49–57. <https://doi.org/10.1016/j.sbi.2017.09.004>.
- Fusco, G., Simone, A.D., Gopinath, T., Vostrikov, V., Vendruscolo, M., Dobson, C.M., Veglia, G., 2014. Direct observation of the three regions in α -synuclein that determine its membrane-bound behaviour. *Nat. Commun.* 5, 3827. <https://doi.org/10.1038/ncomms4827>.
- Galvagnion, C., 2017. The Role of lipids interacting with α -synuclein in the pathogenesis of Parkinson's disease. *J. Park. Dis.* 7, 433–450. <https://doi.org/10.3233/JPD-171103>.
- Galvagnion, C., Buell, A.K., Meisl, G., Michaels, T.C.T., Vendruscolo, M., Knowles, T.P.J., Dobson, C.M., 2015. Lipid vesicles trigger α -synuclein aggregation by stimulating primary nucleation. *Nat. Chem. Biol.* 11, 229–234. <https://doi.org/10.1038/nchembio.1750>.
- Gauthier, S., Feldman, H.H., Schneider, L.S., Wilcock, G.K., Frisoni, G.B., Hardlund, J.H., Moebius, H.J., Bentham, P., Kook, K.A., Wischik, D.J., Schelter, B.O., Davis, C.S., R.T. Staff, Braoud, L., Shamsi, K., Storey, J.M.D., Harrington, C.R., Wischik, C.M., 2016. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. *Lancet Lond. Engl.* 388, 2873–2884. [https://doi.org/10.1016/S0140-6736\(16\)31275-2](https://doi.org/10.1016/S0140-6736(16)31275-2).
- Gedalya, T.B., Loeb, V., Israeli, E., Altschuler, Y., Selkoe, D.J., Sharon, R., 2009. α -Synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. *Traffic* 10, 218–234. <https://doi.org/10.1111/j.1600-0854.2008.00853.x>.
- George, J.M., Jin, H., Woods, W.S., Clayton, D.F., 1995. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. *Neuron* 15, 361–372. [https://doi.org/10.1016/0896-6273\(95\)90040-3](https://doi.org/10.1016/0896-6273(95)90040-3).
- Ghosh, D., Singh, P.K., Sahay, S., Jha, N.N., Jacob, R.S., Sen, S., Kumar, A., Riek, R., Maji, S.K., 2015. Structure based aggregation studies reveal the presence of helix-rich intermediate during α -Synuclein aggregation. *Sci. Rep.* 5, 9228. <https://doi.org/10.1038/srep09228>.
- Goedert, M., Eisenberg, D.S., Crowther, R.A., 2017. Propagation of tau aggregates and neurodegeneration. *Annu. Rev. Neurosci.* 40, 189–210. <https://doi.org/10.1146/annurev-neuro-072116-031153>.
- Goedert, M., Jakes, R., 1990. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. *EMBO J.* 9, 4225–4230.
- Goedert, M., Spillantini, M.G., Crowther, R.A., 1991. Tau proteins and neurofibrillary degeneration. *Brain Pathol. Zurich Switz.* 1, 279–286.
- Goedert, M., Spillantini, M.G., Jakes, R., Rutherford, D., Crowther, R.A., 1989. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. *Neuron* 3, 519–526.
- Goker-Alpan, O., Giasson, B.I., Eblan, M.J., Nguyen, J., Hurtig, H.I., Lee, V.M.-Y., Trojanowski, J.Q., Sidransky, E., 2006. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. *Neurology.* 67, 908–910. <https://doi.org/10.1212/01.wnl.0000230215.41296.18>.
- Golde, T.E., 2014. Open questions for Alzheimer's disease immunotherapy. *Alzheimers Res. Ther.* 6, 3. <https://doi.org/10.1186/alzrt233>.
- Gong, C.X., Liu, F., Grundke-Iqbal, I., Iqbal, K., 2005. Post-translational modifications of tau protein in Alzheimer's disease. *J. Neural Transm. (Vienna)* 112, 813–838. <https://doi.org/10.1007/s00702-004-0221-0>.
- Goode, B.L., Denis, P.E., Panda, D., Radeke, M.J., Miller, H.P., Wilson, L., Feinstein, S.C., 1997. Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly. *Mol. Biol. Cell* 8, 353–365.
- Gould, N., Mor, D.E., Lightfoot, R., Malkus, K., Giasson, B., Ischiropoulos, H., 2014. Evidence of native α -synuclein conformers in the human brain. *J. Biol. Chem.* 289, 7929–7934. <https://doi.org/10.1074/jbc.C113.538249>.
- Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y.C., Zaidi, M.S., Wisniewski, H.M., 1986a. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. *J. Biol. Chem.* 261, 6084–6089.
- Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., Quinlan, M., Wisniewski, H.M., Binder, L.I., 1986b. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. *Proc. Natl. Acad. Sci. U. S. A.* 83, 4913–4917.
- Gurry, T., Ullman, O., Fisher, C.K., Perovic, I., Pochapsky, T., Stultz, C.M., 2013. The dynamic structure of α -synuclein multimers. *J. Am. Chem. Soc.* 135, 3865–3872. <https://doi.org/10.1021/ja310518p>.
- Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E.M., Mandelkow, E., 1994. Domains of tau protein and interactions with microtubules. *Biochem. Mosc.* 33, 9511–9522.
- van Ham, T.J., Thijssen, K.L., Breitling, R., Hofstra, R.M.W., Plasterk, R.H.A., Nollen, E.A.A., 2008. C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. *PLoS Genet.* 4, e1000027. <https://doi.org/10.1371/journal.pgen.1000027>.
- Harada, R., Kobayashi, N., Kim, J., Nakamura, C., Han, S.-W., Ikebukuro, K., Sode, K., 2009. The effect of amino acid substitution in the imperfect repeat sequences of α -synuclein on fibrillation. *Biochim. Biophys. Acta (BBA) - Mol. Basis Dis.* 1792, 998–1003. <https://doi.org/10.1016/j.bbadis.2009.06.010>.
- Hardy, J., Selkoe, D.J., 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 297, 353–356. <https://doi.org/10.1126/science.1072994>.
- Himmler, A., Drechsel, D., Kirschner, M.W., Martin, D.W., 1989. Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. *Mol. Cell. Biol.* 9, 1381–1388.
- Hirokawa, N., Takemura, R., 2005. Molecular motors and mechanisms of directional transport in neurons. *Nat. Rev. Neurosci.* 6, 201–214. <https://doi.org/10.1038/nrn1624>.
- Ilijina, M., Tosatto, L., Choi, M.L., Sang, J.C., Ye, Y., Hughes, C.D., Bryant, C.E., Gandhi, S., Klenerman, D., 2016. Arachidonic acid mediates the formation of abundant alpha-helical multimers of alpha-synuclein. *Sci. Rep.* 6, 33928. <https://doi.org/10.1038/srep33928>.
- Íñigo-Marco, I., Valencia, M., Larrea, L., Bugallo, R., Martínez-Goikotxea, M., Zuriguel, I., Arrasate, M., 2017. E46K α -synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation. *Proc. Natl. Acad. Sci.* 114, E8274–E8283. <https://doi.org/10.1073/pnas.1703420114>.
- Irizarry, M.C., Kim, T.W., McNamara, M., Tanzi, R.E., George, J.M., Clayton, D.F., Hyman, B.T., 1996. Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. *J. Neuropathol. Exp. Neurol.* 55, 889–895.
- Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H.A., Kittel, A., Saitoh, T., 1995. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. *Neuron* 14, 467–475.
- Jacobs, J.R., Stevens, J.K., 1986. Changes in the organization of the neuritic cytoskeleton during nerve growth factor-activated differentiation of PC12 cells: a serial electron microscopic study of the development and control of neurite shape. *J. Cell Biol.* 103, 895–906.
- Janning, D., Igaev, M., Sundermann, F., Bruhmann, J., Beutel, O., Heinisch, J.J., Bakota, L., Piehler, J., Junge, W., Brandt, R., 2014. Single-molecule tracking of tau reveals fast kiss-and-hop interaction with microtubules in living neurons. *Mol. Biol. Cell* 25,

- 3541–3551. <https://doi.org/10.1091/mbc.E14-06-1099>.
- Jao, C.C., Der-Sarkissian, A., Chen, J., Langen, R., 2004. Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. *Proc. Natl. Acad. Sci. U. S. A.* 101, 8331–8336. <https://doi.org/10.1073/pnas.0400553101>.
- Jao, C.C., Hegde, B.G., Chen, J., Haworth, I.S., Langen, R., 2008. Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. *Proc. Natl. Acad. Sci. U. S. A.* 105, 19666–19671. <https://doi.org/10.1073/pnas.0807826105>.
- Jho, Y.S., Zhulina, E.B., Kim, M.W., Pincus, P.A., 2010. Monte carlo simulations of tau proteins: effect of phosphorylation. *Biophys. J.* 99, 2387–2397. <https://doi.org/10.1016/j.bpj.2010.06.056>.
- Jo, E., McLaurin, J., Yip, C.M., George-Hyslop, P.S., Fraser, P.E., 2000. α -Synuclein Membrane Interactions and Lipid Specificity. *J. Biol. Chem.* 275, 34328–34334. <https://doi.org/10.1074/jbc.M107045200>.
- Johnson, S.M., Connelly, S., Fearn, C., Powers, E.T., Kelly, J.W., 2012. The transthyretin amyloidosis: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. *J. Mol. Biol.* 421, 185–203. <https://doi.org/10.1016/j.jmb.2011.12.060>.
- Joshi, P., Vendruscolo, M., 2015. Druggability of intrinsically disordered proteins. *Adv. Exp. Med. Biol.* 870, 383–400. https://doi.org/10.1007/978-3-319-20164-1_13.
- Kadavath, H., Hofele, R.V., Biernat, J., Kumar, S., Tepper, K., Urlaub, H., Mandelkow, E., Zweckstetter, M., 2015a. Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. *Proc Natl Acad. Sci. U. S. A.* 112, 7501–7506. <https://doi.org/10.1073/pnas.1504081112>.
- Kadavath, H., Jaremko, M., Jaremko, L., Biernat, J., Mandelkow, E., Zweckstetter, M., 2015b. Folding of the tau protein on microtubules. *Angew. Chem. Int. Ed. Eng.* 54, 10347–10351. <https://doi.org/10.1002/anie.201501714>.
- Kahle, P.J., Neumann, M., Ozmen, L., Müller, V., Odoj, S., Okamoto, N., Jacobsen, H., Iwatsubo, T., Trojanowski, J.Q., Takahashi, H., Wakabayashi, K., Bogdanovic, N., Riederer, P., Kretschmar, H.A., Haass, C., 2001. Selective Insolubility of α -synuclein in human lewy body diseases is recapitulated in a transgenic mouse model. *Am. J. Pathol.* 159, 2215–2225.
- Kalia, L.V., Lang, A.E., 2015. Parkinson's disease. *Lancet* 386, 896–912. [https://doi.org/10.1016/S0140-6736\(14\)61393-3](https://doi.org/10.1016/S0140-6736(14)61393-3).
- Kanai, Y., Chen, J., Hirokawa, N., 1992. Microtubule bundling by tau proteins in vivo: analysis of functional domains. *EMBO J.* 11, 3953–3961.
- Kar, S., Fan, J., Smith, M.J., Goedert, M., Amos, L.A., 2003. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. *EMBO J.* 22, 70–77. <https://doi.org/10.1093/emboj/cdg001>.
- Kellogg, E.H., Hejab, N.M.A., Poepsel, S., Downing, K.H., DiMaio, F., Nogales, E., 2018. Near-atomic model of microtubule-tau interactions. *Science* 360, 1242–1246. <https://doi.org/10.1126/science.aat1780>.
- Kenner, L., El-Shabrawi, Y., Hutter, H., Forstner, M., Zatloukal, K., Hoefler, G., Preisegger, K.H., Kurzbauer, R., Denk, H., 1994. Expression of three- and four-repeat tau isoforms in mouse liver. *Hepatology* 20, 1086–1089.
- Killinger, B.A., Moszczynska, A., 2016. Characterization of α -synuclein multimer stoichiometry in complex biological samples by electrophoresis. *Anal. Chem.* 88, 4071–4084. <https://doi.org/10.1021/acs.analchem.6b00419>.
- Kim, S., Yun, S.P., Lee, S., Umanah, G.E., Bandaru, V.V.R., Yin, X., Rhee, P., Karuppagounder, S.S., Kwon, S.-H., Lee, H., Mao, X., Kim, D., Pandey, A., Lee, G., Dawson, V.L., Dawson, T.M., Ko, H.S., 2018. GBA1 deficiency negatively affects physiological α -synuclein tetramers and related multimers. *Proc. Natl. Acad. Sci. U. S. A.* 115, 798–803. <https://doi.org/10.1073/pnas.1700465115>.
- Kim, T., Mehta, S.L., Kaimal, B., Lyons, K., Dempsey, R.J., Vemuganti, R., 2016. Poststroke induction of α -synuclein mediates ischemic brain damage. *J. Neurosci.* 36, 7055–7065. <https://doi.org/10.1523/JNEUROSCI.1241-16.2016>.
- Kim, Y.S., Laurine, E., Woods, W., Lee, S.-J., 2006. A novel mechanism of interaction between alpha-synuclein and biological membranes. *J. Mol. Biol.* 360, 386–397. <https://doi.org/10.1016/j.jmb.2006.05.004>.
- Kiss, R., Cszimadia, G., Solti, K., Keresztes, A., Zhu, M., Pickhardt, M., Mandelkow, E., Tóth, G., 2018. Structural basis of small molecule targetability of monomeric tau protein. *ACS Chem. Neurosci.* <https://doi.org/10.1021/acschemneuro.8b00182>.
- Konzack, S., Thies, E., Marx, A., Mandelkow, E.M., Mandelkow, E., 2007. Swimming against the tide: mobility of the microtubule-associated protein tau in neurons. *J. Neurosci.* 27, 9916–9927. <https://doi.org/10.1523/JNEUROSCI.0927-07.2007>.
- Kosik, K.S., Joachim, C.L., Selkoe, D.J., 1986. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. *Proc. Natl. Acad. Sci. U. S. A.* 83, 4044–4048.
- Kosik, K.S., Orecchio, L.D., Bakalis, S., Neve, R.L., 1989. Developmentally regulated expression of specific tau sequences. *Neuron* 2, 1389–1397.
- Kothawala, A., Kilpatrick, K., Novoa, J.A., Segatori, L., 2012. Quantitative analysis of α -synuclein solubility in living cells using split GFP complementation. *PLoS One* 7, e43505. <https://doi.org/10.1371/journal.pone.0043505>.
- Larsen, K.E., Schmitz, Y., Troyer, M.D., Mosharof, E., Dietrich, P., Quazi, A.Z., Savalle, M., Nemani, V., Chaudhry, F.A., Edwards, R.H., Stefanis, L., Sulzer, D., 2006. α -Synuclein overexpression in pc12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. *J. Neurosci.* 26, 11915–11922. <https://doi.org/10.1523/JNEUROSCI.3821-06.2006>.
- Lashuel, H.A., Overk, C.R., Oueslati, A., Masliah, E., 2013. The many faces of α -synuclein: from structure and toxicity to therapeutic target. *Nat. Rev. Neurosci.* 14, 38–48. <https://doi.org/10.1038/nrn3406>.
- Lautenschläger, J., Stephens, A.D., Fusco, G., Ströhl, F., Curry, N., Zacharopoulou, M., Michel, C.H., Laine, R., Nespodivytaya, N., Fantham, M., Pinotsi, D., Zago, W., Fraser, P., Tandon, A., George-Hyslop, P.S., Rees, E., Phillips, J.J., Simone, A.D., Kaminski, C.F., Schierle, G.S.K., 2018. C-terminal calcium binding of α -synuclein modulates synaptic vesicle interaction. *Nat. Commun.* 9, 712. <https://doi.org/10.1038/s41467-018-03111-4>.
- Lázaro, D.F., Rodríguez, E.F., Langohr, R., Shahpasandzadeh, H., Ribeiro, T., Guerreiro, P., Gerhardt, E., Kröhnert, K., Klucken, J., Pereira, M.D., Popova, B., Kruse, N., Mollenhauer, B., Rizzoli, S.O., Braus, G.H., Danzer, K.M., Outeiro, T.F., 2014. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. *PLoS Genet.* 10. <https://doi.org/10.1371/journal.pgen.1004741>.
- Lee, G., Neve, R.L., Kosik, K.S., 1989. The microtubule binding domain of tau protein. *Neuron* 2, 1615–1624.
- Lee, H.-J., Choi, C., Lee, S.-J., 2002. Membrane-bound α -synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. *J. Biol. Chem.* 277, 671–678. <https://doi.org/10.1074/jbc.M107045200>.
- Lee, J.H., Ying, J., Bax, A., 2016. Nuclear magnetic resonance observation of α -synuclein membrane interaction by monitoring the acetylation reactivity of its lysine side chains. *Biochemistry (Mosc)* 55, 4949–4959. <https://doi.org/10.1021/acs.biochem.6b00637>.
- Lee, V.M., Goedert, M., Trojanowski, J.Q., 2001. Neurodegenerative tauopathies. *Annu. Rev. Neurosci.* 24, 1121–1159. <https://doi.org/10.1146/annurev.neuro.24.1.1121>.
- Lee, V.M., Trojanowski, J.Q., 1992. The disordered neuronal cytoskeleton in Alzheimer's disease. *Curr. Opin. Neurobiol.* 2, 653–656.
- Leger, J., Kempf, M., Lee, G., Brandt, R., 1997. Conversion of serine to aspartate imitates phosphorylation-induced changes in the structure and function of microtubule-associated protein tau. *J. Biol. Chem.* 272, 8441–8446.
- Lewis, S.A., Ivanov, I.E., Lee, G.H., Cowan, N.J., 1989. Organization of microtubules in dendrites and axons is determined by a short hydrophobic zipper in microtubule-associated proteins MAP2 and tau. *Nature* 342, 498–505. <https://doi.org/10.1038/342498a0>.
- Liang, B., Tamm, L.K., 2018. Solution NMR of SNAREs, complexin and α -synuclein in association with membrane-mimetics. *Prog. Nucl. Magn. Reson. Spectrosc.* 105, 41–53. <https://doi.org/10.1016/j.pnmrs.2018.02.001>.
- Lindwall, G., Cole, R.D., 1984. Phosphorylation affects the ability of tau protein to promote microtubule assembly. *J. Biol. Chem.* 259, 5301–5305.
- Logan, T., Bendor, J., Toupin, C., Thorn, K., Edwards, R.H., 2017. α -Synuclein promotes dilation of the exocytotic fusion pore. *Nat. Neurosci.* 20, 681–689. <https://doi.org/10.1038/nn.4529>.
- Lokappa, S.B., Suk, J.-E., Balasubramanian, A., Samanta, S., Situ, A.J., Ulmer, T.S., 2014. Sequence and membrane determinants of the random coil-helix transition of α -synuclein. *J. Mol. Biol.* 426, 2130–2144. <https://doi.org/10.1016/j.jmb.2014.02.024>.
- Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H.K., Brundin, P., 2002. Effect of mutant α -synuclein on dopamine homeostasis in a new human mesencephalic cell line. *J. Biol. Chem.* 277, 38884–38894. <https://doi.org/10.1074/jbc.M205518200>.
- Lou, X., Kim, J., Hawk, B.J., Shin, Y.-K., 2017. α -Synuclein may cross-bridge v-SNARE and acidic phospholipids to facilitate SNARE-dependent vesicle docking. *Biochem. J.* 474, 2039–2049. <https://doi.org/10.1042/BCJ20170200>.
- Lundblad, M., Decressac, M., Mattsson, B., Björklund, A., 2012. Impaired neurotransmission caused by overexpression of α -synuclein in nigral dopamine neurons. *Proc. Natl. Acad. Sci.* 109, 3213–3219. <https://doi.org/10.1073/pnas.1200575109>.
- Luth, E.S., Bartels, T., Dettmer, U., Kim, N.C., Selkoe, D.J., 2015. Purification of α -synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. *Biochemistry (Mosc)* 54, 279–292. <https://doi.org/10.1021/bi501188a>.
- Machiya, Y., Hara, S., Arawaka, S., Fukushima, S., Sato, H., Sakamoto, M., Koyama, S., Kato, T., 2010. Phosphorylated α -Synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. *J. Biol. Chem.* 285, 40732–40744. <https://doi.org/10.1074/jbc.M110.141952>.
- Mandelkow, E.M., Schweers, O., Drewes, G., Biernat, J., Gustke, N., Trinczek, B., Mandelkow, E., 1996. Structure, microtubule interactions, and phosphorylation of tau protein. *Ann. N. Y. Acad. Sci.* 777, 96–106.
- Mazzulli, J.R., Xu, Y.-H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A., Sidransky, E., Grabowski, G.A., Krainc, D., 2011. Gaucher disease glucocerebrosidase and α -synuclein form a bidirectional pathogenic loop in synucleinopathies. *Cell* 146, 37–52. <https://doi.org/10.1016/j.cell.2011.06.001>.
- Medina, M., 2018. An overview on the clinical development of tau-based therapeutics. *Int. J. Mol. Sci.* 19. <https://doi.org/10.3390/ijms19041160>.
- Mitchison, T., Kirschner, M., 1984. Dynamic instability of microtubule growth. *Nature* 312, 237–242.
- Mor, D.E., Ugras, S.E., Daniels, M.J., Ischiropoulos, H., 2016. Dynamic structural flexibility of α -synuclein. *Neurobiol. Dis.* 88, 66–74. <https://doi.org/10.1016/j.nbd.2015.12.018>.
- Morimoto, B.H., Schmechel, D., Hirman, J., Blackwell, A., Keith, J., Gold, M., 2013. AL-108-211 study, a double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. *Dement. Geriatr. Cogn. Disord.* 35, 325–336. <https://doi.org/10.1159/000348347>.
- Moussaïd, S., Malany, S., Mehta, A., Vasilie, S., Smith, L.H., McLean, P.J., 2015. Targeting alpha-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies. *Expert Opin. Ther. Targets* 19, 589–603. <https://doi.org/10.1517/14728222.2015.1009448>.
- Mukrasch, M.D., von Bergen, M., Biernat, J., Fischer, D., Griesinger, C., Mandelkow, E., Zweckstetter, M., 2007. The “jaws” of the tau-microtubule interaction. *J. Biol. Chem.* 282, 12230–12239. <https://doi.org/10.1074/jbc.M607159200>.
- Murphy, D.D., Rueter, S.M., Trojanowski, J.Q., Lee, V.M.-Y., 2000. Synucleins are developmentally expressed, and α -synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. *J. Neurosci.* 20, 3214–3220.
- Nakajo, S., Shioda, S., Nakai, Y., Nakaya, K., 1994. Localization of phosphoprotein 14 (PNP 14) and its mRNA expression in rat brain determined by

- immunocytochemistry and in situ hybridization. *Brain Res. Mol. Brain Res.* 27, 81–86.
- Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., Saad, M., DeStefano, A.L., Kara, E., Bras, J., Sharma, M., Schulte, C., Keller, M.F., Arepalli, S., Letson, C., Edsall, C., Stefansson, H., Liu, X., Pliner, H., Lee, J.H., Cheng, R., C. International Parkinson's Disease Genomics, Gen.I. Parkinson's Study Group Parkinson's Research: The Organized, andMe, GenePd, C. NeuroGenetics Research, G. Hussman Institute of Human, I. Ashkenazi Jewish Dataset, H. Cohorts for, E. Aging Research in Genetic, C. North American Brain Expression, C. United Kingdom Brain Expression, C. Greek Parkinson's Disease, G. Alzheimer Genetic Analysis, Ikram, M.A., Ioannidis, J.P., Hadjigeorgiou, G.M., Bis, J.C., Martinez, M., Perlmutter, J.S., Goate, A., Marder, K., Fiske, B., Sutherland, M., Xiromerisiou, G., Myers, R.H., Clark, L.N., Stefansson, K., Hardy, J.A., Heutink, P., Chen, H., Wood, N.W., Houlden, H., Payami, H., Brice, A., Scott, W.K., Gasser, T., Bertram, L., Eriksson, N., Foroud, T., Singleton, A.B., 2014. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nat. Genet.* 46, 989–993. <https://doi.org/10.1038/ng.3043>.
- Narayanan, R.L., Durr, U.H., Bibow, S., Biernat, J., Mandelkow, E., Zweckstetter, M., 2010. Automatic assignment of the intrinsically disordered protein tau with 441-residues. *J. Am. Chem. Soc.* 132, 11906–11907. <https://doi.org/10.1021/ja105657f>.
- Nelson, P.T., Alafuzoff, I., Bigio, E.H., Bouras, C., Braak, H., Cairns, N.J., Castellani, R.J., Crain, B.J., Davies, P., Del Tredici, K., Duyckaerts, C., Frosch, M.P., Haroutunian, V., Hof, P.R., Hulette, C.M., Hyman, B.T., Iwatsubo, T., Jellinger, K.A., Jicha, G.A., Scott, W.K., Gasser, T., Bertram, L., Eriksson, N., Foroud, T., Singleton, A.B., Mann, D.M., Masliah, E., McKee, A.C., Montine, T.J., Morris, J.C., Schneider, J.A., Sonnen, J.A., Thal, D.R., Trojanowski, J.Q., Troncoso, J.C., Wisniewski, T., Woltjer, R.L., Beach, T.G., 2012. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *J. Neuropathol. Exp. Neurol.* 71, 362–381. <https://doi.org/10.1097/NEN.0b013e31825018f7>.
- Nemani, V.M., Lu, W., Berge, V., Nakamura, K., Ono, B., Lee, M.K., Chaudhry, F.A., Nicoll, R.A., Edwards, R.H., 2010. Increased expression of α -synuclein reduces neurotransmitter release by inhibiting synaptic vesicle recluster after endocytosis. *Neuron* 65, 66–79. <https://doi.org/10.1016/j.neuron.2009.12.023>.
- Newton, A.C., 1995. Protein kinase C: structure, function, and regulation. *J. Biol. Chem.* 270, 28495–28498.
- Nuber, S., Rajsobath, M., Minakaki, G., Winkler, J., Müller, C.P., Ericsson, M., Caldarone, B., Dettmer, U., Selkoe, D.J., 2018. Abrogating native α -synuclein tetramers in mice causes a l-dopa-responsive motor syndrome closely resembling Parkinson's disease. *Neuron* 100, 75–90. <https://doi.org/10.1016/j.neuron.2018.09.014>.
- Nuscher, B., Kamp, F., Mehnert, T., Odoy, S., Haass, C., Kahle, P.J., Beyer, K., 2004. Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: a thermodynamics study. *J. Biol. Chem.* 279, 21966–21975. <https://doi.org/10.1074/jbc.M401076200>.
- Nussbaum, R.L., 2018. Genetics of synucleinopathies. *Cold Spring Harb. Perspect. Med.* 8. <https://doi.org/10.1101/cshperspect.a024109>.
- Ouberai, M.M., Wang, J., Swann, M.J., Galvagnon, C., Guilliams, T., Dobson, C.M., Welland, M.E., 2013. α -Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling. *J. Biol. Chem.* 288, 20883–20895. <https://doi.org/10.1074/jbc.M113.478297>.
- Oueslati, A., 2016. Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade? *J. Park. Dis.* 6, 39–51. <https://doi.org/10.3233/JPD-160779>.
- Oueslati, A., Schneider, B.L., Aebischer, P., Lashuel, H.A., 2013. Polo-like kinase 2 regulates selective autophagic α -synuclein clearance and suppresses its toxicity in vivo. *Proc. Natl. Acad. Sci. U. S. A.* 110, E3945–E3954. <https://doi.org/10.1073/pnas.1309991110>.
- Palazzi, L., Bruzzone, E., Bisello, G., Leri, M., Stefani, M., Bucciantini, M., de Laureto, P.P., 2018. Oleuropein aglycone stabilizes the monomeric α -synuclein and favours the growth of non-toxic aggregates. *Sci. Rep.* 8, 8337. <https://doi.org/10.1038/s41598-018-26645-5>.
- Peelaerts, W., Bousset, L., Baekelandt, V., Melki, R., 2018. α -Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences. *Cell Tissue Res.* 373, 195–212. <https://doi.org/10.1007/s00441-018-2839-5>.
- Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., Baekelandt, V., 2015. α -Synuclein strains cause distinct synucleinopathies after local and systemic administration. *Nature* 522, 340–344. <https://doi.org/10.1038/nature14547>.
- Perni, M., Flageimer, P., Limboker, R., Cascella, R., Aprile, F.A., Galvagnon, C., Heller, G.T., Meisl, G., Chen, S.W., Kumita, J.R., Challa, P.K., Kirkegaard, J.B., Cohen, S.I.A., Mannini, B., Barbut, D., Nollen, E.A.A., Cecchi, C., Cremades, N., Knowles, T.P.J., Chiti, F., Zaslouff, M., Vendruscolo, M., Dobson, C.M., 2018. Multistep inhibition of α -Synuclein aggregation and toxicity in vitro and in vivo by trodusquemine. *ACS Chem. Biol.* 13, 2308–2319. <https://doi.org/10.1021/acscchembio.8b00466>.
- Perni, M., Galvagnon, C., Maltsev, A., Meisl, G., Müller, M.B.D., Challa, P.K., Kirkegaard, J.B., Flageimer, P., Cohen, S.I.A., Cascella, R., Chen, S.W., Limboker, R., Sormanni, P., Heller, G.T., Aprile, F.A., Cremades, N., Cecchi, C., Chiti, F., Nollen, E.A.A., Knowles, T.P.J., Vendruscolo, M., Bax, A., Zaslouff, M., Dobson, C.M., 2017. A natural product inhibits the initiation of α -synuclein aggregation and suppresses its toxicity. *Proc. Natl. Acad. Sci. U. S. A.* 114, E1009–E1017. <https://doi.org/10.1073/pnas.1610586114>.
- Pfefferkorn, C.M., Jiang, Z., Lee, J.C., 2012. Biophysics of α -synuclein membrane interactions. *Biochim. Biophys. Acta* 1818, 162–171. <https://doi.org/10.1016/j.bbame.2011.07.032>.
- Pinho, R., Paiva, I., Jerčić, K.G., Fonseca-Ornelas, L., Gerhardt, E., Fahlbusch, C., Garcia-Esparcia, P., Kerimoglu, C., Pavlou, M.A.S., Villar-Piqué, A., Szego, É., Lopes Da Fonseca, T., Odoardi, F., Soeroes, S., Rego, A.C., Fischle, W., Schwamborn, J.C., Meyer, T., Kügler, S., Ferrer, I., Attems, J., Fischer, A., Becker, S., Zweckstetter, M., Borovecki, F., Outeiro, T.F., 2019. Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein. *Hum. Mol. Genet.* <https://doi.org/10.1093/hmg/ddy326>.
- Pirc, K., Ulrih, N.P., 2015. α -Synuclein interactions with phospholipid model membranes: key roles for electrostatic interactions and lipid-bilayer structure. *Biochim. Biophys. Acta Biomembr.* 1848, 2002–2012. <https://doi.org/10.1016/j.bbame.2015.06.021>.
- Porcari, R., Proukakis, C., Waudby, C.A., Bolognesi, B., Mangione, P.P., Paton, J.F.S., Mullin, S., Cabrera, L.D., Penco, A., Relini, A., Verona, G., Vendruscolo, M., Stoppini, M., Tartaglia, G.G., Camilloni, C., Christodoulou, J., Schapira, A.H.V., Bellotti, V., 2015. The H50Q mutation induces a 10-fold decrease in the solubility of α -synuclein. *J. Biol. Chem.* 290, 2395–2404. <https://doi.org/10.1074/jbc.M114.610527>.
- Pranke, I.M., Morello, V., Bigay, J., Gibson, K., Verbavatz, J.-M., Antony, B., Jackson, C.L., 2011. α -Synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding. *J. Cell Biol.* 194, 89–103. <https://doi.org/10.1083/jcb.201011118>.
- Preuss, U., Biernat, J., Mandelkow, E.M., Mandelkow, E., 1997. The "jaws" model of tau-microtubule interaction examined in CHO cells. *J. Cell Sci.* 110 (Pt 6), 789–800.
- Qiang, L., Sun, X., Austin, T.O., Muralidharan, H., Jean, D.C., Liu, M., Yu, W., Baas, P.W., 2018. Tau does not stabilize axonal microtubules but rather enables them to have long labile domains. *Curr. Biol.* 28, 2181–2189. <https://doi.org/10.1016/j.cub.2018.05.045>.
- Raiss, C.C., Braun, T.S., Konings, I.B.M., Grabmayr, H., Hassink, G.C., Sidhu, A., le Feber, J., Bausch, A.R., Jansen, C., Subramanian, V., Claessens, M.M.A.E., 2016. Functionally different α -synuclein inclusions yield insight into Parkinson's disease pathology. *Sci. Rep.* 6, 23116. <https://doi.org/10.1038/srep23116>.
- Roberts, H.L., Brown, D.R., 2015. Seeking a mechanism for the toxicity of oligomeric α -synuclein. *Biomolecules* 5, 282–305. <https://doi.org/10.3390/biom5020282>.
- Rosenberg, K.J., Ross, J.L., Feinstein, H.E., Feinstein, S.C., Israelachvili, J., 2008. Complementary dimerization of microtubule-associated tau protein: Implications for microtubule bundling and tau-mediated pathogenesis. *Proc. Natl. Acad. Sci. U. S. A.* 105, 7445–7450. <https://doi.org/10.1073/pnas.0802036105>.
- Rouzier, R., Rajan, R., Wagner, P., Hess, K.R., Gold, D.L., Stec, J., Ayers, M., Ross, J.S., Zhang, P., Buchholz, T.A., Kuerer, H., Green, M., Arun, B., Hortobagyi, G.N., Symmans, W.F., Pusztai, L., 2005. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. *Proc. Natl. Acad. Sci. U. S. A.* 102, 8315–8320. <https://doi.org/10.1073/pnas.0408974102>.
- Rovere, M., Sanderson, J.B., Fonseca-Ornelas, L., Patel, D.S., Bartels, T., 2018. Refolding of helical soluble α -synuclein through transient interaction with lipid interfaces. *FEBS Lett.* 592, 1464–1472. <https://doi.org/10.1002/1873-3468.13047>.
- Santarella, R.A., Skiniotis, G., Goldie, K.N., Tittmann, P., Gross, H., Mandelkow, E.M., Mandelkow, E., Hoenger, A., 2004. Surface-decoration of microtubules by human tau. *J. Mol. Biol.* 339, 539–553. <https://doi.org/10.1016/j.jmb.2004.04.008>.
- Schneider, S.A., Alcalay, R.N., 2017. Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. *Mov. Disord. Off. J. Mov. Disord. Soc.* 32, 1504–1523. <https://doi.org/10.1002/mds.27193>.
- Scott, C.W., Spreen, R.C., Herman, J.L., Chow, F.P., Davison, M.D., Young, J., Caputo, C.B., 1993. Phosphorylation of recombinant tau by cAMP-dependent protein kinase. Identification of phosphorylation sites and effect on microtubule assembly. *J. Biol. Chem.* 268, 1166–1173.
- Scott, D., Roy, S., 2012. α -Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. *J. Neurosci.* 32, 10129–10135. <https://doi.org/10.1523/JNEUROSCI.0535-12.2012>.
- Shahmoradian, S.H., Lewis, A.J., Genoud, C., Hench, J., Moors, T.E., Navarro, P.P., Castaño-Díez, D., Schweighauser, G., Graff-Meyer, A., Goldie, K.N., Sütterlin, R., Huisman, E., Ingrassia, A., de Gier, Y., Rozenmuller, A.J.M., Wang, J., Paeppe, A.D., Erny, J., Staempfli, A., Hoernschemeyer, J., Großserüschkamp, F., Niedieker, D., El-Mashtoly, S.F., Quadri, M., Van, W.F.J., Jjcken, V., Bonifati, K., Gerwert, B., Bohrmann, S., Frank, M., Britschgi, H., Stahlberg, W.D.J., Van de Berg, M.E. Lauer, 2019. Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. *Nat. Neurosci.* 22, 1099–1109. <https://doi.org/10.1038/s41593-019-0423-2>.
- Sharon, R., Bar-Joseph, I., Mirick, G.E., Serhan, C.N., Selkoe, D.J., 2003. Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. *J. Biol. Chem.* 278, 49874–49881. <https://doi.org/10.1074/jbc.M309127200>.
- Shukla, V., Skuntz, S., Pant, H.C., 2012. Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. *Arch. Med. Res.* 43, 655–662. <https://doi.org/10.1016/j.arcmed.2012.10.015>.
- Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S.W., Hernandez, D.G., Kruger, R., Fiederer, M., Klein, C., Goate, A., Perlmutter, J., Bonin, M., Nalls, M.A., Illig, T., Gieger, C., Houlden, H., Steffens, M., Okun, M.S., Racette, B.A., Cookson, M.R., Foote, K.D., Fernandez, H.H., Traynor, B.J., Schreiber, S., Arepalli, S., Zonoz, R., Gwinn, K., van der Brug, M., Lopez, G., Chanock, S.J., Schatzkin, A., Park, Y., Hollenbeck, A., Gao, J., Huang, X., Wood, N.W., Lorenz, D., Deuschl, G., Chen, H., Riess, O., Hardy, J.A., Singleton, A.B., Gasser, T., 2009. Genome-wide association study reveals genetic risk underlying Parkinson's disease. *Nat. Genet.* 41, 1308–1312. <https://doi.org/10.1038/ng.487>.
- Simon-Sanchez, J., van Hilten, J.J., van de Warrenburg, B., Post, B., Berendse, H.W., Arepalli, S., Hernandez, D.G., de Bie, R.M., Velseboer, D., Scheffer, H., Bloem, B., van Dijk, K.D., Rivadeneira, F., Hofman, A., Uitterlinden, A.G., Rizzu, P., Bochdanovits, Z., Singleton, A.B., Heutink, P., 2011. Genome-wide association study confirms extant PD risk loci among the Dutch. *Eur. J. Hum. Genet.* 19, 655–661. <https://doi.org/10.1038/ejhg.2010.254>.
- Singh, S.K., Dutta, A., Modi, G., 2017. α -Synuclein aggregation modulation: an emerging

- approach for the treatment of Parkinson's disease. *Future Med. Chem.* 9, 1039–1053. <https://doi.org/10.4155/fmc-2017-0016>.
- Soper, J.H., Roy, S., Stieber, A., Lee, E., Wilson, R.B., Trojanowski, J.Q., Burd, C.G., Lee, V.M.-Y., 2008. α -Synuclein-induced aggregation of cytoplasmic vesicles in *Saccharomyces cerevisiae*. *Mol. Biol. Cell* 19, 1093–1103. <https://doi.org/10.1091/mbc.E07-08-0827>.
- Spillantini, M.G., Schmidt, M.L., Lee, V.M.-Y., Trojanowski, J.Q., Jakes, R., Goedert, M., 1997. α -Synuclein in Lewy bodies. *Nature* 388, 839–840. <https://doi.org/10.1038/42166>.
- Spinelli, K.J., Taylor, J.K., Osterberg, V.R., Churchill, M.J., Pollock, E., Moore, C., Meshul, C.K., Unni, V.K., 2014. Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease. *J. Neurosci.* 34, 2037–2050. <https://doi.org/10.1523/JNEUROSCI.2581-13.2014>.
- Steinhilb, M.L., Dias-Santagata, D., Fulga, T.A., Felch, D.L., Feany, M.B., 2007. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. *Mol. Biol. Cell* 18, 5060–5068. <https://doi.org/10.1091/mbc.e07-04-0327>.
- Sun, Q., Gamblin, T.C., 2009. Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization. *Biochem. Mosc.* 48, 6002–6011. <https://doi.org/10.1021/bi900602h>.
- Tell, V., Hilgeroth, A., 2013. Recent developments of protein kinase inhibitors as potential AD therapeutics. *Front. Cell. Neurosci.* 7, 189. <https://doi.org/10.3389/fncel.2013.00189>.
- Tenreiro, S., Reimão-Pinto, M.M., Antas, P., Rino, J., Wawrzycka, D., Macedo, D., Rosado-Ramos, R., Amen, T., Waiss, M., Magalhães, F., Gomes, A., Santos, C.N., Kaganovich, D., Outeiro, T.F., 2014. Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. *PLoS Genet.* 10. <https://doi.org/10.1371/journal.pgen.1004302>.
- Theillet, F.-X., Binolfi, A., Bekei, B., Martorana, A., Rose, H.M., Stuiver, M., Verzini, S., Lorenz, D., van Rossum, M., Goldfarb, D., Selenko, P., 2016. Structural disorder of monomeric α -synuclein persists in mammalian cells. *Nature* 530, 45–50. <https://doi.org/10.1038/nature16531>.
- Trexler, A.J., Rhoades, E., 2012. N-Terminal acetylation is critical for forming α -helical oligomer of α -synuclein. *Protein Sci. Publ. Protein Soc.* 21, 601–605. <https://doi.org/10.1002/pro.2056>.
- Trinczek, B., Biernat, J., Baumann, K., Mandelkow, E.M., Mandelkow, E., 1995. Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. *Mol. Biol. Cell* 6, 1887–1902.
- Tsigelny, I.F., Sharikov, Y., Wrasidlo, W., Gonzalez, T., Desplats, P.A., Crews, L., Spencer, B., Masliah, E., 2012. Role of α -synuclein penetration into the membrane in the mechanisms of oligomer pore formation. *FEBS J.* 279, 1000–1013. <https://doi.org/10.1111/j.1742-4658.2012.08489.x>.
- Unni, V.K., Weissman, T.A., Rockenstein, E., Masliah, E., McLean, P.J., Hyman, B.T., 2010. In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. *PLoS One* 5, e10589. <https://doi.org/10.1371/journal.pone.0010589>.
- Vargas, K.J., Makani, S., Davis, T., Westphal, C.H., Castillo, P.E., Chandra, S.S., 2014. Synucleins regulate the kinetics of synaptic vesicle endocytosis. *J. Neurosci.* 34, 9364–9376. <https://doi.org/10.1523/jneurosci.4787-13.2014>.
- Viennet, T., Wördehoff, M.M., Uluca, B., Poojari, C., Shaykhalishahi, H., Willbold, D., Strodel, B., Heise, H., Buell, A.K., Hoyer, W., Etzkorn, M., 2018. Structural insights from lipid-bilayer nanodiscs link α -synuclein membrane-binding modes to amyloid fibril formation. *Commun. Biol.* 1, 44. <https://doi.org/10.1038/s42003-018-0049-z>.
- Villar-Piqué, A., Lopes da Fonseca, T., Outeiro, T.F., 2016. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. *J. Neurochem.* 139, 240–255. <https://doi.org/10.1111/jnc.13249>.
- Vincent, B.M., Tardiff, D.F., Piotrowski, J.S., Aron, R., Lucas, M.C., Chung, C.Y., Bacherman, H., Chen, Y., Pires, M., Subramaniam, R., Doshi, D.B., Sadlish, H., Raja, W.K., Solís, E.J., Khurana, V., Le Bourdonnec, B., Scannevin, R.H., Rhodes, K.J., 2018. Inhibiting stearyl-CoA desaturase ameliorates α -synuclein cytotoxicity. *Cell Rep.* 25, 2742–2754. e31. <https://doi.org/10.1016/j.celrep.2018.11.028>.
- Viswanadha, R., Sale, W.S., Porter, M.E., 2017. Ciliary motility: regulation of axonemal dynein motors. *Cold Spring Harb. Perspect. Biol.* 9. <https://doi.org/10.1101/cshperspect.a018325>.
- Wang, C., Zhao, C., Li, D., Tian, Z., Lai, Y., Diao, J., Liu, C., 2016. Versatile structures of α -synuclein. *Front. Mol. Neurosci.* 9, 48. <https://doi.org/10.3389/fnmol.2016.00048>.
- Wang, L., Das, U., Scott, D.A., Tang, Y., McLean, P.J., Roy, S., 2014. α -Synuclein multimers cluster synaptic vesicles and attenuate recycling. *Curr. Biol.* 23, 2319–2326. <https://doi.org/10.1016/j.cub.2014.08.027>. CB. 24.
- Wang, W., Perovic, I., Chittiluru, J., Kaganovich, A., Nguyen, L.T.T., Liao, J., Auclair, J.R., Johnson, D., Landeru, A., Simorellis, A.K., Ju, S., Cookson, M.R., Asturias, F.J., Agar, J.N., Webb, B.N., Kang, C., Ringe, D., Petsko, G.A., Pochapsky, T.C., Hoang, Q.Q., 2011. A soluble α -synuclein construct forms a dynamic tetramer. *Proc. Natl. Acad. Sci.* 108, 17797–17802. <https://doi.org/10.1073/pnas.1113260108>.
- Wang, Y., Shi, M., Chung, K.A., Zabetian, C.P., Leverenz, J.B., Berg, D., Srulijes, K., Trojanowski, J.Q., Lee, V.M.-Y., Siderowf, A.D., Hurtig, H., Litvan, I., Schiess, M.C., Peskind, E.R., Masuda, M., Hasegawa, M., Lin, X., Pan, C., Galasko, D., Goldstein, D.S., Jensen, P.H., Yang, H., Cain, K.C., Zhang, J., 2012. Phosphorylated α -synuclein in Parkinson's disease. *Sci. Transl. Med.* 4. <https://doi.org/10.1126/scitranslmed.3002566>. 121ra20.
- Weingarten, M.D., Lockwood, A.H., Hwo, S.Y., Kirschner, M.W., 1975. A protein factor essential for microtubule assembly. *Proc. Natl. Acad. Sci. U. S. A.* 72, 1858–1862.
- West, A., Brummel, B.E., Braun, A.R., Rhoades, E., Sachs, J.N., 2016. Membrane remodeling and mechanics: experiments and simulations of α -synuclein. *Biochim. Biophys. Acta Biomembr.* 1858, 1594–1609. <https://doi.org/10.1016/j.bbamem.2016.03.012>.
- Westphal, C.H., Chandra, S.S., 2013. Monomeric synucleins generate membrane curvature. *J. Biol. Chem.* 288, 1829–1840. <https://doi.org/10.1074/jbc.M112.418871>.
- Wietek, J., Haralampiev, I., Amoussouvi, A., Herrmann, A., Stöckl, M., 2013. Membrane bound α -synuclein is fully embedded in the lipid bilayer while segments with higher flexibility remain. *FEBS Lett.* 587, 2572–2577. <https://doi.org/10.1016/j.febslet.2013.06.034>.
- Wilcock, G.K., Gauthier, S., Frisoni, G.B., Jia, J., Hardlund, J.H., Moebius, H.J., Benthani, P., Kook, K.A., Schelter, B.O., Wischik, D.J., Davis, C.S., R.T. Staff, Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J.M.D., Harrington, C.R., Wischik, C.M., 2018. Potential of low dose leuco-methylthionium bis(hydromethanesulphonate) (Imtm) monotherapy for treatment of mild Alzheimer's disease: Cohort analysis as modified primary outcome in a phase III clinical trial. *J. Alzheimers Dis. JAD.* 61, 435–457. <https://doi.org/10.3233/JAD-170560>.
- Wischik, C.M., R.T. Staff, Wischik, D.J., Benthani, P., Murray, A.D., Storey, J.M.D., Kook, K.A., Harrington, C.R., 2015. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. *J. Alzheimers Dis. JAD.* 44, 705–720. <https://doi.org/10.3233/JAD-142874>.
- Wolozin, B.L., Pruchnicki, A., Dickson, D.W., Davies, P., 1986. A neuronal antigen in the brains of Alzheimer patients. *Science* 232, 648–650.
- Wong, Y.C., Krainc, D., 2017. α -Synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. *Nat. Med.* 23, 1–13. <https://doi.org/10.1038/nm.4269>.
- Wood, J.G., Mirra, S.S., Pollock, N.J., Binder, L.I., 1986. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau. *Proc. Natl. Acad. Sci. U. S. A.* 83, 4040–4043.
- Xu, J., Kao, S.-Y., Lee, F.J.S., Song, W., Jin, L.-W., Yankner, B.A., 2002. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. *Nat. Med.* 8, 600–606. <https://doi.org/10.1038/nm0602-600>.
- Xu, J., Wu, X.-S., Sheng, J., Zhang, Z., Yue, H.-Y., Sun, L., Sgobio, C., Lin, X., Peng, S., Jin, Y., Gan, L., Cai, H., Wu, L.G., 2016. α -Synuclein mutation inhibits endocytosis at mammalian central nerve terminals. *J. Neurosci.* 36, 4408–4414. <https://doi.org/10.1523/JNEUROSCI.3627-15.2016>.
- Yamasaki, T.R., Holmes, B.B., Furman, J.L., Dhavale, D.D., Su, B.W., Song, E.-S., Cairns, N.J., Kotzbauer, P.T., Diamond, M.I., 2019. Parkinson's disease and multiple system atrophy have distinct α -synuclein seed characteristics. *J. Biol. Chem.* 294, 1045–1058. <https://doi.org/10.1074/jbc.RA118.004471>.
- Ysselstein, D., Joshi, M., Mishra, V., Griggs, A.M., Asiago, J.M., McCabe, G.P., Stanciu, L.A., Post, C.B., Rochet, J.-C., 2015. Effects of impaired membrane interactions on α -synuclein aggregation and neurotoxicity. *Neurobiol. Dis.* 79, 150–163. <https://doi.org/10.1016/j.nbd.2015.04.007>.
- Zhang, Z., Dai, C., Bai, J., Xu, G., Liu, M., Li, C., 2014. Ca²⁺ modulating α -synuclein membrane transient interactions revealed by solution NMR spectroscopy. *Biochim. Biophys. Acta Biomembr.* 1838, 853–858. <https://doi.org/10.1016/j.bbamem.2013.11.016>.
- Zhang, Z., Jiang, X., Xu, D., Zheng, W., Liu, M., Li, C., 2018. Calcium accelerates SNARE-mediated lipid mixing through modulating α -synuclein membrane interaction. *Biochim. Biophys. Acta.* <https://doi.org/10.1016/j.bbamem.2018.03.025>.
- Zhu, X.C., Cao, L., Tan, M.S., Jiang, T., Wang, H.F., Lu, H., Tan, C.C., Zhang, W., Tan, L., Yu, T., 2017. Association of Parkinson's disease GWAS-linked Loci with Alzheimer's disease in han chinese. *Mol. Neurobiol.* 54, 308–318. <https://doi.org/10.1007/s12035-015-9649-5>.